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As of 2018, the United States National Institutes of Health estimate that over half a 
billion people worldwide are affected by autoimmune disorders. Though these conditions are 
prevalent, treatment options remain relatively poor, relying primarily on various forms of 
immunosuppression which carry potentially severe side effects and often lose effectiveness 
overtime. Given this, new forms of therapy are urgently needed. We propose small-
interfering RNA (siRNA) for hypervariable regions of the T-cell receptor β-chain gene 
(TCRb) as a highly targeted, novel means of therapy for the treatment of autoimmune 
disorders. 
In this experiment, both human Jurkat and human CD8+ anti-HPV T-cells were 
purchased and their mRNA isolated. A novel method for the production of siRNA was then 
employed to create an siRNA “cocktail” for particular hypervariable regions within TCRb. 
Additionally, a conventional method was employed to create siRNA for single 
computationally determined regions of TCRb. Synthesized siRNA was subsequently coated 
with lipofectamine to facilitate transfection. The coated siRNAs were then applied to 
respective patient cells at 10 pmol for 24h. Gene knockdown was quantified by qPCR, while 
cell viability was quantified by MTS assay and trypan blue count. 
While all siRNA species demonstrated a significant level of knockdown on TCRb, 
CD3, and CD137 (P < 0.05), the siRNA “cocktail” showed the highest level of TCRb 
knockdown (P = 0.0406). Moreover, siRNA developed in this manner had an extremely 
small effect on T-cells lacking affinity for different antigens (low off targeting). The effect 




The results of this experiment demonstrate not only the high potency of the described 
siRNAs on gene knockdown, but the low levels of off-targeting they exhibit. Based on this, 
we believe that both the previously described siRNA cocktail as well as computationally 




Chapter 1.  Introduction 
 As of 2018, the United States National Institutes of Health (NIH) estimate that over half a 
billion people worldwide are affected by various autoimmune conditions (NIH, 2018). These 
conditions range from cosmetic disorders (such as psoriasis), to potentially life-threatening 
diseases (such as lupus). In addition to presenting in a wide range of severity, the financial 
burden put onto patients with these conditions varies widely as well. In the case of a relatively 
mild condition such as psoriasis, the financial burden on a patient actively getting treatment for 
the condition can be as low as $1757 annually (Evans, 2016). Though this is certainly not an 
insubstantial financial burden, it contrasts heavily with conditions such as multiple sclerosis, 
lupus, or Crohn’s disease. The annual cost of conditions such as these easily exceed $60,000 per 
year for many patients, with the majority of this cost being composed of direct medical expenses 
(Optum Health, 2019). 
Over the past few decades, there have been many advances in the field of molecular 
biology, particularly in the area of its application to medicine. One of the most impactful of these 
technologies over these years has come from the advent of RNA interference (RNAi) technologies 
(Daneholt, 2006). RNA interference is a process by which specific genes are effectively silenced 
with short strands of inhibitory RNA molecules (Daneholt, 2006). One type of RNA molecule 
which has been shown to effectively accomplish this is small interfering RNA (siRNA) (Agrawal 
et al, 2003). The first step of siRNA creation involves the synthesis of a strand of double stranded 
RNA (dsRNA), and subsequently enabling its entrance into the cytoplasm of a mammalian cell 
(Agrawal et al, 2003). Upon entering a cell, this dsRNA is shortly thereafter bound by the protein 
DICER, which cleaves the dsRNA into siRNA (Agrawal et al, 2003). Key features of the resulting 
siRNA molecules are their typical length of 21-25 nucleotides, as well as a pair of overhanging 
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nucleotides on both 3’ ends, hydroxylated 3’ ends, and phosphorylated 5’ ends (Agrawal et al, 
2003). After the siRNA has been formed, RNA-induced silencing complex (RISC) loads a single 
strand (typically the antisense strand) into its complex (Agrawal et al, 2003). The loaded RISC 
then proceeds to bind messenger RNA (mRNA) strands complimentary to the loaded siRNA 
strand, cleaving and inactivating the mRNA in the process (Agrawal et al, 2003). This disruption 
in translation leads to silencing of the target gene as the proteins it codes for will ultimately not be 
created. 
 In 1999, when the effects of siRNA were first reported, its potential medical applications 
were immediately evident (Baulcombe, 1999). As the genes for DICER are relatively conserved 
among mammals, the gene silencing effects of siRNA potentially allow for treatment of diseases 
in which a human’s own cells are responsible for all of, or part, of the pathology. This includes 
conditions ranging from cancer, autoimmunity, or even some viral infections. In fact, not 
surprisingly, in the past decade there have arisen clinical trials for drugs which utilize siRNA in 
the treatment of cancer, as well as, Ebola (Oha and Parkb, 2009). Unfortunately, the research for 
use of RNAi technologies in autoimmune diseases has been relatively sparse, likely owing 
primarily to the mechanism by which autoimmune diseases cause their pathology. Autoimmune 
disease pathology is caused by a small minority of immune cells acting in such a way that causes 
damage to the host (Harrison's Principles of Internal Medicine, 2012). Unfortunately, the 
differences between the cells causing autoimmune pathology versus those which are necessary for 
normal biological function and immunity are scarce. As a result, most RNAi therapies which seek 
to alleviate or eliminate a particular pathology will also end up causing damage to the healthy 
portion of the host’s immune system. As a result, therapies for autoimmune diseases which seek 
to use RNAi technology will typically target genes which are significantly up-regulated as part of 
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the condition’s pathology, such as pro-inflammatory factors in rheumatoid arthritis (Pauley and 
Cha, 2013). This being the case, the ideal target for treatment of an autoimmune disorder would 
be a gene expressed exclusively in the cell lines responsible for the pathology of the condition. 
Fortunately, there are a few genes that produce mRNA which differ between individual immune 
cell lines. These include the genes responsible for antibody production in B cells as well as antigen 
receptor chain production in T cells (Janeways immunobiology, 2012). 
To deal with the vast array of pathogens which are able to infect humans, the body has 
evolved a remarkable system commonly referred to as adaptive immunity. In contrast with the 
innate immune system, the adaptive immune system has evolved to be able to deal with novel 
pathogens, allowing the body to rid itself of diseases not experienced by previous generations 
(Janeways immunobiology, 2012). This is achieved by the generation of variation in antigen 
recognition chains for T cells, and antibodies for B cells, a process which occurs in a series of steps 
which over the past century have become fairly well understood. Though the processes are 
extremely similar, for the sake of time, focus will be taken on antigen receptor chain in T cells (as 
they are more relevant to the scope of these writings). 
To understand the gene arrangement coding for antigen receptor chain development, one 
must first understand the structure of the chains themselves. In 95% of cases, a T cell receptor is 
composed of both an alpha, and a 𝛽 chain (Janeways immunobiology, 2012). Each of these chains 
is formed by an amino terminal variable (V) region, which composes the antigen recognition 
portion of the receptor, and a constant (C) region, which composes the transmembrane portion of 
the receptor (Janeways immunobiology, 2012). Though the processes which govern the 
development of both of these chains are similar, the development of the β chain will be the focus 
of this chapter (the chain most pertinent in this experiment). 
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Development of the β chain is controlled by a gene segment designed to create the 
opportunity for a large degree of diversity for the antigen receptor it will ultimately encode. The β 
chain is composed of many of each of four separate segment types: variable (V) regions, joining 
(J) segments, diversity (D) segments, and constant (C) segments. These genes are arranged in an 
order as follows: 52 V regions, followed by a D region, followed by 6 J segments, followed by a 
C region, followed by an additional D region, followed by 7 additional J segments, followed by a 
final C region (Janeways immunobiology, 2012). The genes encoding the β chain receptor are 
located on chromosome 7 (Caccia et al, 1984). To produce a functional β chain, the variable, 
diversity, and joining regions undergo rearrangement and splicing to one another through a series 
of processes. This newly spliced gene is then linked to the constant gene regions to form the 
completed gene product which will ultimately produce the mRNA responsible for β chain 
production (Janeways immunobiology, 2012). Because of this series of gene recombinations, it is 
highly unlikely that the gene segment encoding for any two separate lines of T cells will be the 
same. 
The proliferation of both B and T cells is dependent on how effective they are at 
recognizing antigen. With some exception, cells which successfully recognize antigen receive a 
variety of signals which stimulate their proliferation (Janeways immunobiology, 2012). Cells that 
do not receive these signals, however, tend not to reproduce and over time begin to die off 
(Janeways immunobiology, 2012). The lifespan of these cells ranges greatly, with the half-life of 
CD8 T cells being around 37 days (McDonagh and Bell, 1995) while their CD4 counterparts have 
been shown to survive for as long as 17 years in humans (Imamishi et al, 2014). 
The gene rearrangements that cause the diversity seen in both T and B cells are an 
evolutionary necessity for the destruction of a variety of pathogens. These same rearrangements, 
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however, can potentially be problematic for the wellbeing of the same system they are trying to 
protect, as is the case in autoimmune disorders. Autoimmune disorders are caused when B or T 
cell receptors become specific for motifs on the host’s own tissues (Janeways immunobiology, 
2012). These tissue molecules which are targeted are termed autoantigens, and can vary greatly 
between individuals. The immune system has a number of mechanisms, as well as a vetting 
process, designed to prevent the occurrence of autoantigen (Janeways immunobiology, 2012). This 
being the case, however, given the rate at which new cells are produced, even a small slip in the 
system can lead to autoimmunity. An example of a disease in which this occurs is multiple 
sclerosis. In the case of multiple sclerosis, T cells gain specificity for protein present in the myelin 
sheath, the protective and insulative coating found surrounding neurons (Huseby et aI, 2012). The 
recognition of myelin by a T cell causes inflammation as well as a disruption of the blood-brain 
barrier, leading to a variety of severely damaging neurological effects for the victim (Minager and 
Alexander, 2003). 
Though significant advances in autoimmune disease treatment have been made over the 
past several decades, there is a large requirement for improvement. Most current therapies focus 
on down regulation of the immune system as a whole, as opposed to targeting the specific immune 
cell lines causing the pathology. As expected, this leads to a variety of problems and side effects, 
including global immune suppression. These side effects severely limit the dosing of these drugs, 
as high and long-term use of these therapies can ultimately lead to the patient’s immune system 
becoming severely compromised (Williamson and Berger, 2015). It is therefore critical that 
treatments which are highly specific for the agents causing the specific pathology be the primary 
focus of the development of future therapies targeted at autoimmune disorders. 
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To develop therapies with high specificity, it is necessary to be able to identify and exploit 
the subtle differences between cells. In the case of autoimmune disorders, this means 
differentiating between specific lines of B or T cells. Given that there is genetic diversity among 
these lines in the form of the genes encoding the receptors found on their surfaces, these same 
genetic differences offer a viable target for the creation of a therapy with a high degree of 
specificity. Given that RNAi technology gives scientists the ability to target specific gene 
sequences with relatively high fidelity, RNAi can likely offer a highly effective means of treating 
a wide array of autoimmune disorders, provided the ability to elucidate the gene sequences 
required for B cell and T cell receptor production.  
Therapy with a method as specific as RNAi in autoimmune conditions also has a number 
of other implications. If the cells lines affected by RNAi are unable to produce antigen receptors, 
they will, therefore, be unable to recognize antigen. A cell which is unable to recognize antigen 
will not receive proliferation signals, and slowly will begin to die off. This being the case, RNAi 
may potentially offer a means of therapy which can lead to remission of autoimmune diseases over 
time, as the cell lines causing the pathology may gradually begin to die off. This contrasts greatly 
with most current therapies, which show a high degree of relapse soon after treatment has been 
halted. This research aims to develop the methods required to synthesize siRNA for the T cell 
receptor beta chain (TCRb gene). Additionally, this research seeks to test the various siRNA 
species created on human immune cells ex-vivo to demonstrate their effectiveness. 
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Chapter 2. The 51 Primer Method 
2.1 Introduction 
 To Create siRNA Targeting the TCRb gene of a particular line of T cells, it is necessary 
to know the mRNA sequence of the TCRb gene within these cells. Though this may seem simple 
in principle, it presents quite a technical challenge due to the high levels of variation that occur 
within this gene. For a researcher to be able to sequence a gene, they must first amplify the gene 
to sufficient levels for analysis using Polymerase chain reaction (PCR). Unfortunately, one of the 
requirements to carry out a successful PCR reaction is designing primers targeting sequences 
bracketing the gene of interest. Unfortunately, due to the high levels of variation within the 
TCRb gene, this is not possible using conventional methods. As previously discussed, there are 
roughly 52 different variable regions which can be found on the 5’ end of the mRNA for the 
TCRb gene. Additionally, there are two different variations (though highly similar) of the 
constant region found on the 3’ end of the mRNA. Given this information, a conventional 
method used for the amplification of the TCRb gene has been to make two separate primer 
mixes, one containing primers for the 51 variable regions and the other containing primers for 
both of the constant region variants. One benefit of this method is the relative ease of 
amplification once the primer mixes have been created (given that a large number of aliquots can 
be made). Additionally, though many primers are required, these primers are extremely 
inexpensive (costing only approximately $6 USD at the time of this writing) and come in 







The methods used in this experiment were adapted from Robins et al. The primers used 
were taken from United States Patent Application: US 2016/0319340 A1. These Primers as well 
as primer pCB1 can be found in appendix A. 
2.2.1 Creation of Primer Mix 
 Primers were ordered dry and desalted from Thermo Scientific and resuspended to a 
concentration of 200mM. One microliter of each of the 51 variable region primers were 
combined on ice and pipetted gently to mix. In a second microfuge tube, pCB1 primer (a primer 
which binds to both potential constant regions) was resuspended to 10mM. 
2.2.2 mRNA Isolation 
RNA was isolated from Both Human Jurkat and Human CD8+ anti-HPV cells. This was 
accomplished using an Absolutely RNA Nanoprep Kit (Agilent). Approximately 10,000 cells of 
each sample were combined with 100 μl lysis buffer and 0.7 μl Beta-Mercaptoethanol. These 
samples were then vortexed for approximately one minute until well homogenized. After 
homogenization, 100 μl sulfolane was added to the lysate and the samples were again vortexed 
for approximately five seconds. It was noted that the samples became warm during this process. 
Samples were then transferred to individual RNA-binding spin cups and centrifuged at 12,000 x 
g for one minute. The filtrate was immediately discarded. Three hundred microliters of low-salt 
wash buffer was then added to the spin column and centrifuged at 12,000 x g for an additional 
minute with the filtrate again being discarded. The spin column was then centrifuged at 12,000 x 
g for two minutes in order to completely dry the spin column. After patting the edges of the 
column dry with a Kim-Wipe, 2.5 microliters RNase-Free DNase I was combined with 12.5 
microliters DNase digestion buffer. The full 15 microliters of completed DNase solution was 
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then added to the spin column and allowed to incubate in a 37°C bead-bath for 15 minutes. After 
incubation, 300 microliters high-salt wash buffer was added to the column and centrifuged at 
12,000 x g for one minute. The filtrate was again discarded and 300 microliters of low-salt wash 
buffer was added to the column and centrifuged at 12,000 x g for one minute. After discarding 
the filtrate, the column was spun for an additional three minutes to dry the column. After patting 
the column dry with a kim-wipe, the cup was placed into a fresh two milliliter collection tube. 
The provided elution buffer was warmed to 60°C, and 10 microliters of elution buffer was 
quickly added to each column and allowed to sit for two minutes at room temperature. The 
columns were then spun at 12,000 x g for five minutes and capped. A NanoDrop™ 2000 unit 
(Thermo Scientific) was used to quantify the concentration of RNA within the resulting 
solutions. NanoDrop™ analysis of the samples revealed a concentration of 10.3 
nanograms/microliter for the human Jurkat cells and 5.1 nanograms/microliter for the human 
CD8+ Anti-HPV cells. 
2.2.3 Reverse Transcription 
For both the Human Jurkat and Human CD8+ Anti-HPV cells reverse transcription of the 
mRNA was performed. To do this, 20 nanograms of RNA (determined by nanodrop) was 
combined with one microliter oligo (dT)20 (50 micromolar) and 1 microliter of a 10 mM dNTP 
mix (10mM dATP, dGTP, dCTP, dTTP). The samples were then brought to 13 microliters using 
PCR-grade water. These samples were then heated to 65°C for 5 minutes followed by immediate 
incubation on ice for 1 minute. 
Using the reagents provided with a superscript RT kit, four microliters 5x first strand 
buffer, one microliter 0.1 M DTT, and one microliter Superscript III reverse transcriptase (200 
units/microliter) were added to each sample. Additionally, 1 microliter RNaseIN™ was added to 
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each sample to maximize cDNA yield. The samples were then mixed by gentle pipetting and 
allowed to incubate at 50°C for one hour. Following this incubation, the reaction was inactivated 
by heating at 70°C for 15 minutes. 
To remove the mRNA strands from their cDNA counterparts, RNaseH (New England 
Biolabs) was used. This was accomplished by adding 2.1 microliters RNaseH buffer and 1 
microliter RNase H to each sample. These samples were then incubated at 37°C for 20 minutes 
and immediately frozen and stored at -80°C. 
2.2.4 PCR Amplification 
 In triplicate, both completed cDNA samples were combined in a PCR plate on ice with 
the following reagents: five microliters SYBR™ Green Master Mix (Thermo Scientific), 0.5 
microliters variable region primer mix, 0.5 microliters pCB1 primer, 1 microliter of respective 
sample, and 3 microliters PCR grade water. 
 After the reagents were combined, the PCR reaction was carried out using the following 
parameters: 
Step Temperature Time 
Denaturation 94°C 2 minutes 
40 Cycles:     
Denaturation 94°C 15 seconds 
Annealing and 
Extension 53°C 1 minute 
Fluorescence read     
 
A positive result would be indicated by fluorescence in the respective qPCR reactions following 
amplification. 
2.3 Results 
 None of the three samples for each of the two reactions showed any fluorescence during 
the qPCR reaction. It should be noted that this experiment was repeated an additional time with 
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similar results, however in the second run of the experiment one of the wells for human Jurkat 
cells began to show fluorescence after 19 cycles. Due to the fact that no other wells in the 
triplicate reaction showed any fluorescence, it is assumed that this false positive was the result of 
primer dimerization or contamination. 
2.4 Discussion 
 It is uncertain why the 52-primer method was not successful. The theory behind the 
method was sound and the protocols outlined were relatively standard (though applied in a 
highly specialized manner). It is possible that the experiment failed due to human error (a primer 
not being added properly), though it is also possible that the sheer number of primers used in this 
experiment caused unanticipated interactions which prevented the reaction from working. 
2.5 Notes 
1. Bustin, S. (2002). Quantification of mRNA using real-time reverse transcription PCR 
(RT-PCR): trends and problems. Journal of Molecular Endocrinology, 23–39. 
https://doi.org/10.1677/jme.0.029002 
 














Chapter 3. C Tailing Method 
3.1 Introduction 
 Due to the failures experienced with the 51-primer method discussed in the previous 
chapter, it became necessary to explore alternative options for sequencing the TCRb gene. To 
accomplish this, a spin on the traditional “C-tailing” method was used. Though the methods used 
to achieve sequencing using C-tailing are relatively complex, the principle behind the method is 
fairly simple. In order to elucidate the sequence of a given DNA strand, the DNA strand must 
first be amplified using PCR. For a researcher to perform PCR, both a forward and reverse 
primer are required. Creating a forward and reverse primer requires the researcher to know the 
sequence of areas bracketing the DNA sequence of interest. In the case of mRNA for a gene like 
TCRb, this is problematic as the sequence of interest is highly randomized. Fortunately, because 
we are interested in the mRNA sequence of TCRb, we know that the 3’ end of the sequence of 
interest will be the constant region of TCRb, which is relatively conserved. Because of this, a 
primer for a sequence that is homologous for both constant region variants can be used. This 
means that we are only left needing a reverse primer to sequence TCRb. Unfortunately, the 5’ 
end of the mRNA (and therefore the 3’ end of its cDNA after reverse transcription) for TCRb 
begins with the hypervariable region of the gene. This means that under ordinary circumstances, 
a single primer would be unable to provide sufficient specificity to allow for amplification of the 
gene. This is remedied in the G-tailing method using an enzyme known as terminal 
deoxynucleotidyl transferase (TdT). TdT adds random nucleotides to the 3’ end of any given 
DNA sequence. To exploit this, we can allow TdT to perform its function on the cDNA of the 
TCRb gene except do so in a solution that is devoid of all nucleotides except for cytosine. By 
doing this, the cDNA has a poly-C repeat added to its 3’ end. This poly-C repeat allows us to 
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design a reverse primer in the form of a Poly-G primer. Desoxyinosine residues are interspersed 
within the sequence to lower the melting temperature of the primer and allow for successful PCR 
amplification. Verification of a successful assay can be performed by qPCR where amplification 
(indicated by fluorescence in the PCR reactions) is indicative that the Tailing reaction is 
successful. 
3.2 Methods 
3.2.1 mRNA Isolation 
 RNA was isolated from Both Human Jurkat and Human CD8+ anti-HPV cells. This was 
accomplished using an Absolutely RNA Nanoprep Kit (Agilent). Approximately 10,000 cells of 
each sample were combined with 100 μl lysis buffer and 0.7 μl Beta-Mercaptoethanol. These 
samples were then vortexed for approximately one minute until well homogenized. After 
homogenization, 100 μl sulfolane was added to the lysate and the samples were again vortexed 
for approximately five seconds. It was noted that the samples became warm during this process. 
Samples were then transferred to individual RNA-binding spin cups and centrifuged at 12,000 x 
g for one minute. The filtrate was immediately discarded. Three hundred microliters of low-salt 
wash buffer was then added to the spin column and centrifuged at 12,000 x g for an additional 
minute with the filtrate again being discarded. The spin column was then centrifuged at 12,000 x 
g for two minutes in order to completely dry the spin column. After patting the edges of the 
column dry with a Kim-Wipe, 2.5 microliters RNase-Free DNase I was combined with 12.5 
microliters DNase digestion buffer. The full 15 microliters of completed DNase solution was 
then added to the spin column and allowed to incubate in a 37°C bead-bath for 15 minutes. After 
incubation, 300 microliters High-salt wash buffer was added to the column and centrifuged at 
12,000 x g for one minute. The filtrate was again discarded and 300 microliters of low-salt wash 
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buffer was added to the column and centrifuged at 12,000 x g for one minute. After discarding 
the filtrate, the column was spun for an additional three minutes to dry the column. After patting 
the column dry with a kim-wipe, the cup was placed into a fresh two milliliter collection tube. 
After warming the provided elution buffer to 60°C, 10 microliters of elution buffer were quickly 
added to the column and allowed to sit for two minutes at room temperature. The column was 
then spun at 12,000 x g for five minutes and capped. A NanoDrop™ 2000 unit (Thermo 
Scientific) was used to quantify the concentration of RNA within the resulting solution. 
NanoDrop™ analysis of the samples revealed a concentration of 8.9 nanograms/microliter for 
the human Jurkat cells and 7.8 nanograms/microliter for the human CD8+ Anti-HPV cells. 
3.2.2 Reverse Transcription 
For both the Human Jurkat and Human CD8+ Anti-HPV cells reverse transcription of the 
mRNA was performed. To do this, 20 nanograms of RNA (determined by nanodrop) was 
combined with one microliter oligo (dT)20 (50 micromolar) and 1 microliter of a 10 mM dNTP 
mix (10mM dATP, dGTP, dCTP, dTTP). The samples were then brought to 13 microliters using 
PCR-grade water. These samples were then heated to 65°C for 5 minutes followed by immediate 
incubation on ice for 1 minute. 
Using the reagents provided with a superscript RT kit, 4 microliters 5x first strand buffer, 
one microliter 0.1 M DTT, and 1 microliter Superscript III reverse transcriptase (200 
units/microliter) were added to each sample. Additionally, 1 microliter RNaseIN™ was added to 
each sample to maximize cDNA yield. The samples were then mixed by gentle pipetting and 
allowed to incubate at 50°C for one hour. Following this incubation, the reaction was inactivated 
by heating at 70°C for 15 minutes. 
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To remove the mRNA strands from their cDNA counterparts, RNaseH (New England 
Biolabs) was used. This was accomplished by adding 2.1 microliters RNaseH buffer and 1 
microliter RNase H to each sample. These samples were then incubated at 37°C for 20 minutes 
and immediately frozen and stored at -80°C. 
3.2.3 DNA Cleanup 
 DNA cleanup was performed using a GeneJET PCR purification kit (Thermo Scientific). 
This step was necessary to remove any residual dNTPs which would be problematic for the 
future TdT enzyme reaction. To do this, a 1:1 volume of binding buffer (approximately 25 
microliters) was added to the previously created samples and thoroughly mixed. It was noted that 
the samples were a bright yellow, indicating that the pH of the solution was correct for the assay. 
The 50 microliters of this solution were then added to the GeneJet purification column and 
centrifuged at 8,000 x g for 30 seconds, discarding the permeate. Seven hundred microliters 
wash buffer was then added to each sample and centrifuged for 30 seconds, discarding the 
permeate. The columns were then transferred to new microfuge tubes and centrifuged at 8,000 x 
g for one minute to ensure that the columns were dry. The columns were again transferred to 
fresh microfuge tubes and 20 microliters elution buffer was added to each column. After 
centrifuging at 8,000 x g for a final minute, the samples were quantified via NanoDrop™ and 
stored at -80°C for G-Tailing. NanoDrop™ assessment of the samples showed a concentration of 
2.2 nanograms/microliter for the human Jurkat sample and 2.4 nanograms/microliter for the 
human CD8+ anti-HPV cells. 
3.2.4 Poly-C Tailing 
 Poly-C tailing was carried out using a TdT enzyme reaction kit purchased from New 
England Biolabs. In clean microfuge tubes on ice, the following reagents were added in order: 5 
17 
 
microliters 5x TDT buffer, 18.5 microliters of the clean cDNA product from previous steps, 0.5 
microliters 10mM dCTP, and 1.5 microliters TdT enzyme. This reaction mix was then pipetted 
gently to mix and gently spun to collect all reagents in the bottom of the microfuge tubes. The 
reaction mixes were then incubated at 37°C for 15 minutes for the tailing reaction to proceed. 
After the incubation, the samples were placed into a 70°C bead bath for 10 minutes to stop the 
reaction by inactivating the enzyme. 
3.2.5 Verification of Product Formation 
 The formation of properly formed product was verified using qPCR. Five microliters 
SYBR™ Green PCR Master mix (Thermo Scientific) was combined on ice with 0.5 microliters 
10mM pGI primer (primer which anneals to the poly-C sequence), 0.5 microliters 10mM pCB1 
primer, two microliters of the tailed DNA product, and two microliters PCR grade water (The 
sequence of both primers used in this reaction can be found in Appendix A). This was done in 
triplicate for both samples. Thermocycling was then executed under the following parameters: 
Step Temperature Time 
Denaturation 94°C 2 minutes 
40 Cycles:     
Denaturation 94°C 15 seconds 
Annealing and 
Extension 53°C 1 minute 
Fluorescence read     
 
3.3 Results 
 All six samples that were run showed fluorescence by 30 cycles, indicating that the C-
tailing reaction worked as intended. It should be noted that the product obtained from the PCR 
reaction would not be ideal for sequencing as the specificity of amplification is quite low as a 
result of effectively using only a single primer (due to the possibility of other unwanted genes 
being amplified as well). Future reactions that required sequencing of the PCR product used a 
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nested primer sequence in which two primers for the constant region were used to improve 
specificity. 
3.4 Notes 
1. Bustin, S. (2002). Quantification of mRNA using real-time reverse transcription PCR 
(RT-PCR): trends and problems. Journal of Molecular Endocrinology, 23–39. 
https://doi.org/10.1677/jme.0.029002 
 




3. Thermo Scientific. “Product Information Thermo Scientific GeneJET Genomic DNA 
Purification Kit.” Thermo Fisher Scientific, 2016. 
 




5. Wälchli, S., Løset, G., Kumari, S., Johansen, J., Yang, W., Sandliw, I., Olweus, J. 2011. 





Chapter 4. Synthesis of SiRNA Using a Whole Strand “Shotgun” Method 
4.1 Introduction 
 One major issue with developing siRNA for a particular gene is the high level of 
variability in siRNA effectiveness. Although a number of algorithms have been developed to 
predict the effectiveness of a given siRNA, these formulas are far from infallible and very often 
have no correlation with real-life applications. 
 The following methods were created as a highly reliable, low-cost technique to create 
large quantities of SiRNA for a given TCRb gene. The general idea behind the method is as 
follows: 
• First, the cDNA for the mRNA of the TCRb gene is amplified using conventional PCR as 
well as the previously described C-Tailing method. A nested PCR reaction is used to 
increase specificity (needed as the pGI primer is not specific to the cDNA of interest). 
• Next, a T7 promoter is hybridized to the cDNA samples using overhanging primers 
incorporated into a PCR reaction 
• The dsDNA is melted and using the new T7 promoter attached to the cDNA templates, 
transcription to RNA is carried out using T7 RNA polymerase. 
• The complimentary RNA strands created in the previous transcription reaction are 
allowed to slowly cool and anneal to form dsRNA strands. 
• After cleaning the dsRNA using a column chromatography mini-prep, an RNase III 
enzyme (DICER) is used to cleave the dsRNA strands into a series of siRNA molecules. 
• The siRNAs are then cleaned by glycogen/ethanol precipitation for use. 
4.2 Methods 
Note: all primer sequences can be found in appendix A. 
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4.2.2 Nested PCR Reactions 
 The PCR reactions in this portion of the experiment were carried out using Titanium™ 
Taq DNA polymerase (Clontech). In two separate microfuge tubes on ice, the 15 microliters of 
DNA created using the previously described C-tailing method for both human Jurkat and human 
CD8+ anti-HPV cells were combined with 0.5 microliters pGI primer, 0.5 microliters pCB1 
primer, one microliter dNTP mix, five microliters 10x taq buffer, one microliter taq polymerase, 
and 27 microliters PCR grade water. After all reagents were added to their respective microfuge 
tubes, the samples were mixed by gentle pipetting. Samples were then split into three separate 
aliquots on a PCR plate (for a total of six total samples) and thermocycled under the following 
parameters: 
Step Temperature Time 
Denaturation 94°C 2 minutes 
20 Cycles:     







Fluorescence read (only 
applicable to wells 
using SYBR™ Green)     
 
A parallel reaction using SYBR™ Green was carried out to verify that the PCR 
amplification was successful. In duplicate, one microliter of the respective DNA samples were 
combined with five microliters SYBR™ Green master mix as well as 0.5 microliters pGI primer 
and 0.5 microliters pCB1 primer and three microliters PCR grade water. Fluorescence in these 
samples using SYBR green after thermocycling could be used as a positive indication that the 
reaction using Titanium™ Taq polymerase was successful. 
After this first PCR reaction had completed, a second nested PCR reaction using a second primer 
set was executed.  Five microliters of DNA from each sample were placed into two separate 
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microfuge tubes on ice. To these tubes, the following reagents were added: Five microliters 10x 
taq buffer, 0.5 microliters pGI primer, 0.5 microliters pCB2 primer, one microliter dNTP mix, 
one microliter 50x Titanium™ taq polymerase, and 37 microliters PCR grade water. After all 
reagents were added to their respective microfuge tubes, the samples were mixed by gentle 
pipetting. Samples were then split into three separate aliquots on a PCR plate (for a total of six 
total samples) and thermocycled under the following parameters: 
Step Temperature Time 
Denaturation 94°C 2 minutes 
20 Cycles:     







Fluorescence read (only 
applicable to wells 
using SYBR™ Green)     
   
 
Again, a parallel reaction using SYBR™ Green was carried out to verify that the PCR 
amplification was successful. In duplicate, one microliter of the respective DNA samples was 
combined with five microliters SYBR™ Green master mix as well as 0.5 microliters pGI primer 
and 0.5 microliters pCB2 primer and three microliters PCR grade water. Fluorescence in these 
samples using SYBR green after thermocycling could be used as a positive indication that the 
nested reaction using Titanium™ Taq polymerase was successful. 
4.2.3 DNA Cleanup 
DNA cleanup was performed using a GeneJET PCR purification kit (Thermo Scientific). 
This step was necessary to remove any residual dNTPs which would be problematic for the 
future TdT enzyme reaction. To do this, a 1:1 volume of binding buffer (approximately 25 
microliters) was added to the previously created samples and thoroughly mixed. It was noted that 
the samples were a bright yellow, indicating that the pH of the solution was correct for the assay. 
22 
 
The 50 microliters of this solution were then added to the GeneJet purification column and 
centrifuged at 8,000 x g for 30 seconds, discarding the permeate. Seven hundred microliters 
wash buffer was then added to each sample and centrifuged for 30 seconds, discarding the 
permeate. The columns were then transferred to new microfuge tubes and centrifuged at 8,000 x 
g for one minute to ensure that the columns were dry. The columns were again transferred to 
fresh microfuge tubes and 20 microliters elution buffer was added to each column. After 
centrifuging at 8,000 x g for a final minute, the microfuge tubes were capped and stored at -80°C 
for later steps. 
4.2.4 T7 Promoter Hybridization 
In two separate microfuge tubes on ice, five microliters of clean DNA from each sample 
in the previous steps were combined with 0.5 microliters pGI+Promoter primer, 0.5 microliters 
pCB2+Promoter primer, one microliter dNTP mix, five microliters 10x taq buffer, one microliter 
taq polymerase, and 37 microliters PCR grade water. After all reagents were added to their 
respective microfuge tubes, the samples were mixed by gentle pipetting. Samples were then split 
into three separate aliquots on a PCR plate (for a total of six total samples) and thermocycled 
under the following parameters: 
Step Temperature Time 
Denaturation 94°C 2 minutes 
10 Cycles:     







Fluorescence read (only 
applicable to wells 
using SYBR™ Green)     
 
A parallel reaction using SYBR™ Green was carried out to verify that the PCR 
amplification was successful. In duplicate, one microliter of the respective DNA samples were 
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combined with five microliters SYBR™ Green master mix as well as 0.5 microliters 
pGI+promoter primer and 0.5 microliters pCB2+promoter primer and three microliters PCR 
grade water. Fluorescence in these samples using SYBR green after thermocycling could be used 
as a positive indication that the reaction using Titanium™ Taq polymerase was successful. 
After this first PCR reaction had completed, a second nested PCR reaction using a second 
primer set was executed.  Five microliters of DNA from each sample were placed into two 
separate microfuge tubes on ice. To these tubes, the following reagents were added: Five 
microliters 10x taq buffer, one microliter T7 Promoter Primer, one microliter dNTP mix, one 
microliter 50x Titanium™ taq polymerase, and 37 microliters PCR grade water. After all 
reagents were added to their respective microfuge tubes, the samples were mixed by gentle 
pipetting. Samples were then split into three separate aliquots on a PCR plate (for a total of six 
total samples) and thermocycled under the following parameters: 
Step Temperature Time 
Denaturation 94°C 2 minutes 
20 Cycles:     







Fluorescence read (only 
applicable to wells 
using SYBR™ Green)     
 
Again, a parallel reaction using SYBR™ Green was carried out to verify that the PCR 
amplification was successful. In duplicate, one microliter of the respective DNA samples was 
combined with five microliters SYBR™ Green master mix as well as one microliter T7 Promoter 
Primer and three microliters PCR grade water. Fluorescence in these samples using SYBR green 
after thermocycling could be used as a positive indication that the nested reaction using 
Titanium™ Taq polymerase was successful. 
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4.2.5 DNA Cleanup 
DNA cleanup was performed using a GeneJET PCR purification kit (Thermo Scientific). 
This step was necessary to remove any residual dNTPs which would be problematic for the 
future TdT enzyme reaction. To do this, a 1:1 volume of binding buffer (approximately 25 
microliters) was added to the previously created samples and thoroughly mixed. It was noted that 
the samples were a bright yellow, indicating that the pH of the solution was correct for the assay. 
The 50 microliters of this solution were then added to the GeneJet purification column and 
centrifuged at 8,000 x g for 30 seconds, discarding the permeate. Seven hundred microliters 
wash buffer was then added to each sample and centrifuged for 30 seconds, discarding the 
permeate. The columns were then transferred to new microfuge tubes and centrifuged at 8,000 x 
g for one minute to ensure that the columns were dry. The columns were again transferred to 
fresh microfuge tubes and 20 microliters elution buffer was added to each column. After 
centrifuging at 8,000 x g for a final minute, the microfuge tubes were capped and stored at -80°C 
for later steps. 
4.2.6 Transcription 
 For both the human Jurkat and human CD8+ anti-HPV cell DNA product, transcription 
was carried out using T7 RNA Polymerase (New England Biolabs). To transcribe the respective 
DNA samples, the following were combined in a PCR plate on ice: Two microliters of the 
respective DNA sample, four microliters PCR grade water, 10 microliters 2xNTP, two 
microliters T7 reaction buffer, 0.5 microliters RNASEin (thermo scientific), and two microliters 
T7 enzyme mix. It should be noted that there seemed to be a precipitate formed in the T7 
reaction buffer that was re-dissolved by vortexing for several minutes. After mixing the reagents 
by gentle pipetting, the samples were incubated in a PCR thermocycler unit for 2 hours at 37°C. 
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4.2.7 Hybridization of ssRNA 
 After the incubation stage of the previous step, the PCR thermocycler was held at 75°C 
for 5 minutes followed by a steady reduction to 4°C over a one hour period. 
4.2.8 RNA Cleanup 
 RNA samples were cleaned using an RNeasy™ miniprep kit (Qiagen). To do this, each 
sample had 20 microliters 70% EtOH added and mixed by pipetting. After this, the whole sample 
was transferred to an RNeasy™ spin column and centrifuged at 8,000 x g for 15 seconds, 
discarding the flow-through. Seven hundred microliters of reconstituted buffer RW1 was then 
added, centrifuged for 15 seconds at 8,000 x g, and the flow-through again discarded. Five 
hundred microliters buffer RPE was added to the spin columns and centrifuged at 8,000 x g for 
15 seconds. A second 500 microliters buffer RPE was then added and centrifuged for two 
minutes to ensure that the column was completely dry. Finally, the Rneasy spin column was 
placed into a clean 1.5 microliter collection tube. Thirty microliters RNase-Free water warmed to 
37°C (warmed to increase yield) was then added to the spin column membrane and spun at 8,000 
x g for one minute. After this, siRNA synthesis was immediately proceeded to in order to 
maximize yield (RNA has poor stability). 
4.2.9 SiRNA Synthesis by RNase III 
 To create siRNA, Shortcut® RNase III (New England Biolabs) was used. The following 
were combined on ice: The entire 30 microliters dsRNA from the previous step, 10 microliters 
10x Shortcut Reaction Buffer, 10 microliters Shortcut RNase III, 10 microliters 10x MnCL2, and 
40 microliters PCR grade water. This solution was then mixed by gentle pipetting and incubated 




4.2.10 SiRNA Precipitation 
 To precipitate the siRNAs, one-tenth volume 3M NaOAc, 2 microliters Rnase-free 
Glycogen, and 360 microliters ice-cold 95% EtOH were added. This solution was then kept at -
20°C for two hours. After incubation at -20°C, the samples were spun for 15 minutes at 12,000 x 
g. At this point, a small pellet had formed at the bottom of each tube. The supernatant was 
removed by gentle pipetting, taking care not to disturb the siRNA pellet. After wiping the top of 
the microfuge tubes with a kim-wipe, an additional 300 microliters of ice-cold 80% ethanol 
pipetted over the pellet and allowed to sit for 10 minutes at room temperature. The samples were 
again centrifuged at 12,000 x g for 15 minutes and the supernatant removed by gentle pipetting. 
The RNA was then resuspended in 30 microliters molecular biology grade water and stored at -
80°C for future experimentation.  
4.3 Results 
 All PCR samples ran successfully as indicated by fluorescence in the parallel qPCR 
reactions using SYBR green.  
 
4.4 Notes 
1. Biolabs, New England. “T7 RNA Polymerase.” NEB, New England Biolabs, 2019, 
www.neb.com/products/m0251-t7-rna-polymerase#Product%20Information. 
 
2. Fedorov, Y., Anderson, E., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., 
Leake, D., Marshall, W., Khvorova, A. 2006. “Odd-targeting Effects by siRNA can 
Induce Toxic Phenotype”. RNA Society. 12:1188-1196. 
 




4. Thermo Scientific. “Product Information Thermo Scientific GeneJET Genomic DNA 








6. Wälchli, S., Løset, G., Kumari, S., Johansen, J., Yang, W., Sandliw, I., Olweus, J. 2011. 






Chapter 5. Synthesis of SiRNA Designed with a Computational Method 
Note: This section contains code snippets written in the visual basic language. The full source 
code can be found in Appendix B. 
5.1 Introduction 
 Although the previously described “shotgun” SiRNA synthesis method has many 
benefits, including low chance of failure in RNA interference, it presents a number of potential 
issues if intended for use as a therapeutic. Of these issues, the largest is likely the fact that with 
so many created siRNA species, some siRNA species will exhibit off-targeting effects. These 
effects can be avoided by creating specific siRNA species which have been blast searched 
against the human genome to avoid siRNA species with high levels of homology to genes that 
are unrelated to our target. 
 As previously mentioned, a major hurdle in creating siRNA for a particular gene is the 
high level of variability in siRNA effectiveness. Fortunately, many algorithms have been 
proposed based on meta data of successful siRNA species. Taken together, these algorithms can 
predict the effectiveness of a given siRNA species with a fair degree of accuracy. Of the 
prediction algorithms, one of the most popular and highly tested are the algorithms from 
Reynalds et al 2004. Roughly, the algorithms put forward by Reynalds et al state the following: 
• An siRNA should have an overhang of two U residues on the 3’ end of both strands. 
• There should be an A residue in the 3 position 
• There should be an A residue in the 19th position 
• There should not be a G in position 13 
• There should be a U in position 10 
• There should not be a C or G in position 19 
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• There should not be a palindromic sequence of 4 or more bases 
• The GC content of the siRNA should fall between 30% and 52% 
• There should be at least one A or U residue in positions 15 through 19 
• There should not be a run of four consecutive A residues 
• There should not be a run of four consecutive U residues 
After having established the rules for the design of siRNA in this experiment, it became 
necessary to consider the method of synthesis used to create the siRNA. As the siRNA is 
intended as a therapeutic, it would be ideal for whatever method is being used to be high 
throughput, have a low turnaround time, and require minimal sophisticated equipment. Based on 
these parameters, it was decided that a conventional oligo-based synthesis method be used (an 
example of an oligo-based siRNA design kit being a Silencer™ siRNA construction kit (Thermo 
scientific)). The general principle behind this type of method is that a DNA oligo for the 
complimentary sequence of the siRNA intended to be synthesized is purchased. To this DNA 
oligo, a T7 promoter is added. The compliment of this DNA sequence with a T7 promoter is also 
purchased. Both DNA strands are then transcribed into complimentary single stranded RNAs and 
allowed to anneal in such a way that they form completed siRNAs. 
The methods required to both identify potential siRNA targeting sites as well as create 
templates to synthesize said RNAs are both complicated and time consuming. Due to the size 
and randomness of the TCRb gene, it is not viable to do most of these calculations by hand. To 
alleviate this problem, a computer program which automates the siRNA targeting site 
identification and subsequent DNA template design was created. This chapter outlines both the 
design philosophy and code used to meet this goal. 
5.1.1 Creation of Scoring System and Implementation of Algorithms 
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 For each discriminant put forward by Reynalds et al, a corresponding function was 
created. Each of these functions receives a variable “siRNA” (as text) and returns a true or false 
value as to whether or not the rules of the discriminant are met. 
The following function checks position 3 of a given siRNA for the nucleotide “A”. If the 
nucleotide is present, the Boolean value “True” (1) is returned. Otherwise, “False” (0) is 
returned. 
Function Discrim1(ByVal siRNA As String) As Boolean 
    Dim bool As Boolean = False 
    If GetChar(siRNA, 3) = "a" Or GetChar(siRNA, 3) = "A" Then 
        bool = True 
    End If 
    Return bool 
End Function 
 
This function looks for an “A” nucleotide in position 19 and returns the Boolean value “True” if 
it is found or “False” if it is not. 
Function Discrim2(ByVal siRNA As String) As Boolean 
    Dim bool As Boolean = False 
    If GetChar(siRNA, 19) = "a" Or GetChar(siRNA, 19) = "A" Then 
        bool = True 
    End If 





In this function, “G” is checked for in position 13. If G is not found, “True” is returned (This is a 
negative discriminant). 
Function Discrim3(ByVal siRNA As String) As Boolean 
    Dim bool As Boolean = False 
    If Not GetChar(siRNA, 13) = "g" And Not GetChar(siRNA, 13) = "G" Then 
        bool = True 
    End If 
    Return bool 
End Function 
 
This function checks for a “U” residue in position 10. If the U residue is found, “True” is 
returned. 
Function Discrim4(ByVal siRNA As String) As Boolean 
 
    Dim bool As Boolean = False 
    If GetChar(siRNA, 10) = "u" Or GetChar(siRNA, 10) = "U" Then 
        bool = True 
    End If 





The below function checks position 19 for the absence of both “C” and “G” residues. If neither 
are present, “True” is returned (negative discriminant). 
Function Discrim5(ByVal siRNA As String) As Boolean 
    Dim bool As Boolean = False 
    If Not GetChar(siRNA, 19) = "c" And Not GetChar(siRNA, 19) = "C" And Not 
GetChar(siRNA, 19) = "g" And Not GetChar(siRNA, 19) = "G" Then 
        bool = True 
    End If 
    Return bool 
End Function 
 
The following function checks for even numbered palindromes of length 4 or greater. If a 
Palindrome is found, “True” is returned. 
Function Palindrome_check_4_units(ByVal siRNA As String) As Boolean 
    Dim bool As Boolean = False 
    Dim reverse_sequence As String = Strings.StrReverse(siRNA) 
    Dim count As Integer = 0 
    Dim forward As String = Nothing 
    Dim reverse As String = Nothing 
    Do While count < siRNA.Length - 4 
        forward = siRNA.Remove(0, count) 
        forward = siRNA.Substring(0, 4) 
        Dim count2 As Integer = 0 
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        Do While count2 < siRNA.Length - 4 
            reverse = siRNA.Remove(0, count) 
            reverse = siRNA.Substring(0, 4) 
            If forward = reverse Then 
                bool = True 
            End If 
            count2 = count2 + 1 
        Loop 
        count = count + 1 
    Loop 
    Return bool 
End Function 
 
This function checks for odd numbered palindromes of length 5 or greater. If a palindrome is 
found, “True” is returned. 
Function Palindrome_check_5_units(ByVal siRNA As String) As Boolean 
    Dim bool As Boolean = False 
    Dim reverse_sequence As String = Strings.StrReverse(siRNA) 
    Dim count As Integer = 0 
    Dim forward As String = Nothing 
    Dim reverse As String = Nothing 
    Do While count < siRNA.Length - 5 
        forward = siRNA.Remove(0, count) 
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        forward = siRNA.Substring(0, 5) 
        Dim count2 As Integer = 0 
        Do While count2 < siRNA.Length - 5 
            reverse = siRNA.Remove(0, count) 
            reverse = siRNA.Substring(0, 5) 
            If forward = reverse Then 
                bool = True 
            End If 
            count2 = count2 + 1 
        Loop 
        count = count + 1 
    Loop 
    Return bool 
End Function 
 
This function Checks for the GC content of a given siRNA strand and returns a corresponding 
value between 0 and 1.0. 
Function Get_GC(ByVal siRNA As String, siRNA_length As Integer) As Double 
    Dim GC_content As Double = 0 
    Dim count As Integer = 0 
    Dim ATU_count As Integer = 0 
    Do While count < siRNA.Length 
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        If GetChar(siRNA, count + 1) = "a" Or GetChar(siRNA, count + 1) = "A" Or 
GetChar(siRNA, count + 1) = "t" Or GetChar(siRNA, count + 1) = "T" Or GetChar(siRNA, 
count + 1) = "u" Or GetChar(siRNA, count + 1) = "U" Then 
            ATU_count = ATU_count + 1 
        End If 
        count = count + 1 
    Loop 
    GC_content = 1 - (ATU_count / siRNA_length) 
    Return GC_content 
End Function 
 
The below function looks for A, U, or T residues between residues 15 and 19. The function 
returns “True” if a residue is found. 
Function AUT_in_15_through_19(ByVal sirna As String, sirna_Length As Integer) As Boolean 
    Dim bool As Boolean = False 
    Dim char15 As Char = GetChar(sirna, 15) 
    Dim char16 As Char = GetChar(sirna, 16) 
    Dim char17 As Char = GetChar(sirna, 17) 
    Dim char18 As Char = GetChar(sirna, 18) 
    Dim char19 As Char = GetChar(sirna, 19) 
    If char15 = "a" Or char15 = "A" Or char15 = "t" Or char15 = "T" Or char15 = "u" Or char15 = 
"U" Then 
        bool = True 
36 
 
    End If 
    If char16 = "a" Or char16 = "A" Or char16 = "t" Or char16 = "T" Or char16 = "u" Or char16 = 
"U" Then 
        bool = True 
    End If 
    If char17 = "a" Or char17 = "A" Or char17 = "t" Or char17 = "T" Or char17 = "u" Or char17 = 
"U" Then 
        bool = True 
    End If 
    If char18 = "a" Or char18 = "A" Or char18 = "t" Or char18 = "T" Or char18 = "u" Or char18 = 
"U" Then 
        bool = True 
    End If 
    If char19 = "a" Or char19 = "A" Or char19 = "t" Or char19 = "T" Or char19 = "u" Or char19 = 
"U" Then 
        bool = True 
    End If 
    Return bool 
End Function 
 
This function checks for a leading “AA” sequence in the mRNA being targeted (The siRNA 
compliment will be “UU”). 
Function Check_for_AA(ByVal siRNA As String) As Boolean 
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    Dim AA_Bool As Boolean = False 
    Dim Score As Integer = 0 
    If GetChar(siRNA, 1) = "A" Or GetChar(siRNA, 1) = "a" Then 
        Score = Score + 1 
    End If 
    If GetChar(siRNA, 2) = "A" Or GetChar(siRNA, 2) = "a" Then 
        Score = Score + 1 
    End If 
    If Score = 2 Then 
        AA_Bool = True 
    End If 
    Return AA_Bool 
End Function 
 
In this function, the algorithm checks for a running repeat of either four “A” or four “T” 
residues. If this is found, “True” is returned. 
Function Check_for_running_T_or_A(ByVal siRNA As String, sirna_length As Integer) As 
Boolean 
    Dim Poly_T_A As Boolean = False 
    Dim count As Integer = 0 
    Dim tempstring As String = Nothing 
    Do While count < sirna_length - 4 
        tempstring = siRNA 
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        tempstring = tempstring.Remove(0, count) 'remove leading characters in temporary string 
        tempstring = tempstring.Substring(0, 4) ' trims temporary string to 4 characters 
        If tempstring = "aaaa" Or tempstring = "AAAA" Or tempstring = "TTTT" Or tempstring = 
"tttt" Or tempstring = "UUUU" Or tempstring = "uuuu" Then 
            Poly_T_A = True 
            count = 9999999  
 'breaks loop 
        End If 
        count = count + 1 
    Loop 
    Return Poly_T_A 
End Function 
 
5.1.2 SiRNA Scoring 
 Scoring of siRNA candidates is based on the level of statistical significance assigned to 
each individual discriminant by Reynalds et al. The respective “point value” of 7 of the 11 
discriminants can be seen in the following list: 
A in position 3 16.8 
A in position 19 22.1 
No G in position 13 14.1 
U in position 10 30.6 
No C or G in position 19 25.6 
No palindromes of 4 or more 10.1 




Four of the eleven discriminants were considered absolutely necessary for an siRNA to be 
successful (and were therefore not assigned a score). These four discriminants can be seen in the 
t below: 
No four consecutive A residues 
No four consecutive U residues 
The GC content must fall between 30% and 52% 
There should not be a palindrome of 4 or more 
bases 
 
To apply the respective scores to each siRNA, the following code was used: 
    Do While count < codelength - SiRNA_Length 
        Dim GC_content As Double = Get_GC(DataArray(count), SiRNA_Length) 
        If Discrim1(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 16.8 
        End If 
        If Discrim2(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 22.1 
        End If 
        If Discrim3(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 14.1 
        End If 
        If Discrim4(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 30.6 
        End If 
        If Discrim5(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 25.6 
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        End If 
        If not Palindrome_check_4_units(DataArray(count)) And not 
Palindrome_check_5_units(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 10.1 
        End If 
        If AUT_in_15_through_19(DataArray(count), DataArray(count).Length) Then 
            SiRNA_Score = SiRNA_Score + 16.9 
        End If 
        If Check_for_running_T_or_A(DataArray(count), DataArray(count).Length) Then 
            'Lowers score to a level where they will be ignored by future algorithms 
            SiRNA_Score = SiRNA_Score - 20000 
        End If 
        If Not Check_for_AA(DataArray(count)) Then 
            'Lowers score to a level where they will be ignored by future algorithms 
            SiRNA_Score = SiRNA_Score - 20000 
        End If 
        If Get_GC(DataArray(count), DataArray(count).Length) < 0.3 Or 
Get_GC(DataArray(count), DataArray(count).Length) > 0.52 Then 
            'Lowers score to a level where they will be ignored by future algorithms 
            SiRNA_Score = SiRNA_Score - 20000 
        End If 
        ScoreArray(count) = SiRNA_Score 
        SiRNA_Score = 0 
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        count = count + 1 
    Loop 
 
By assigning a score of “-20,000” to siRNAs that do not meet the necessary discriminants, these 
siRNA are never returned to the user. 
5.1.3 Identification of V, D, J, and C Regions 
 For the user’s information, an algorithm was designed to identify the V, D, J, and C 
regions of a given RNA input. This was simply done by exploiting the fact that the V region is 
typically 340 residues long, the D region is 16 residues long, and the J region is 50 residues long. 
The following code was used to split the regions: 
    If Not CheckBox1.Checked Then 
        Do While TextBox1.Text.Length > count 
            If count <= 340 Then 
                RichTextBox2.Text = RichTextBox2.Text + GetChar(TextBox1.Text, count + 1) 
            End If 
            If count > 340 And count <= 356 Then 
                RichTextBox3.Text = RichTextBox3.Text + GetChar(TextBox1.Text, count + 1) 
            End If 
            If count > 356 And count <= 406 Then 
                RichTextBox4.Text = RichTextBox4.Text + GetChar(TextBox1.Text, count + 1) 
            End If 
            If count > 406 Then 
                RichTextBox5.Text = RichTextBox5.Text + GetChar(TextBox1.Text, count + 1) 
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            End If 
            count = count + 1 
        Loop 
    End If 
 
5.1.4 Addition of T7 Promoter 
 As the goal of this program is to advise the user on what DNA oligoes are required to 
create the siRNA of interest, an algorithm was used to systematically create complimentary 
primer pairs with T7 promoters designed to synthesize complimentary RNA strands which will 
create siRNA when hybridized. This is accomplished with the following code: 
    Do While count < codelength - SiRNA_Length 
        If ScoreArray(count) > 0 Then 
            'Displays siRNA candidate with respective score adjacent 
            RichTextBox1.Text = RichTextBox1.Text + DataArray(count) + "   " + 
ScoreArray(count).ToString + vbCrLf 
            'Displays siRNA candidate with the promoter sequence added 
            RichTextBox6.Text = RichTextBox6.Text + DataArray(count) + "CCTGTCTC" + "        
" + ScoreArray(count).ToString + vbCrLf 
            'Removes leading AA to get compliment without overhang 
            DataArray(count).Remove(0, 2) 




            RichTextBox6.Text = RichTextBox6.Text + "AA" + 
Convert_to_Compliment(DataArray(count)) + "CCTGTCTC" + vbCrLf + vbCrLf 
        End If 
       count = count + 1 
    Loop 
 
5.1.5 User Interface 
 The user interface for this program was designed to both be all-inclusive and easily 
accessible. The two primary user inputs are the TCRb sequence as well as the desired siRNA 
length (with 23 as the optimal default). Additionally, the user may specify if their input only 
contains the CDR3 region, is the RNA compliment, or is the cDNA of the TCRb sequence. The 
user may also specify if they would like a number of residues trimmed from the front or back of 
the TCRb sequence (as interior sequences tend to be more favorable for inhibition by siRNA). 
The code for all of these user inputs (all of which are code-commented) can be found in 




Figure 5.1. TCRb siRNA Solver user interface 
 




Figure 5.2. TCRb siRNA Solver user interface after having run data 
 
5.2 Conclusion 
 The described program was tested for accuracy against hand calculations for the same 
TCRb sequences. After extensive debugging, it was found that the calculations were identical in 
all cases. Additionally, the calculations done by the program are not only far less time 
consuming but are also far less error prone (especially given the complexity required to make 
this type of calculation). 
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To test the efficacy of the various siRNA formulations previously described, qPCR was 
utilized. The qPCR experiment looked at the ability of each siRNA formulation to knock down 
three genes: TCRb, CD3, and CD137. In theory, TCRb should be directly knocked down as a 
result of the siRNA causing the TCRb mRNA to be degraded directly. CD3 is a co-receptor 
which conjugates to a completed T cell receptor upon its migration to the cell surface. A 
feedback loop decreases the level of CD3 in the absence of TCRb expression due to translated 
CD3 receptors being unable to migrate to the T cell surface. The final gene, CD137, is expressed 
by activated T cells. T cells which do not express their receptor complexes are unable to undergo 
activation and are therefore incapable of expressing CD137 at normal levels. β-actin was also 
measured to normalize the genes of interest. 
 In addition to testing for the expression of the aforementioned genes, cell viability was 
also tested. This is important as the intended mechanism of the siRNA is to prevent the cells 
from expressing their receptors while leaving their viability unaffected. Although T cells which 
do not express their receptors should be unable to proliferate at any significant level, the lack of 
receptors should not be directly toxic to the cells. Cell viability analysis was done both by MTS 
assay as well as direct count with trypan blue. 
 An important consideration for this type of therapy is that the siRNA synthesized for one 
particular T cell line should not be effective against other cell lines. This is important because the 
major benefit of using siRNA synthesized with the methods previously described is the isolation 
of the effect to only “pathogenic” T cell lines (as opposed to all cell lines being affected with a 
therapy such as corticosteroids). Additionally, negative controls were used to ensure any effects 
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witnessed were a result of the siRNA cocktails and not the vectors being used to deliver the 
therapies (lipofectamine™ (Thermo Scientific)). 
6.2 Methods 
6.2.1 SiRNA Synthesis Using a “Shotgun” Method 
For both human Jurkat, and human CD8+ anti-HPV cells, siRNA was synthesized using 
the previously described “shotgun” method. These siRNAs were frozen and stored at -80⁰C for 
further experimentation. 
6.2.2 SiRNA Synthesis Using a Computational Method 
For both human Jurkat, and human CD8+ anti-HPV cells, the mRNA sequence of their 
respective TCRb genes were sequenced. After the sequence had been obtained for both samples, 
the three highest scoring primer pairs were determined using the previously created siRNA 
solver program. These primer pairs were purchased for use in the synthesis of siRNA for the 
respective TCRb genes. The six primer pairs used for siRNA synthesis and their corresponding 
scores can be found in the following table. 
Table 6.1. List of Oligos and Corresponding Scores. 




































After the primers had been obtained, synthesis of siRNA was carried out using a 
Silencer™ siRNA construction kit (Thermo Scientific). To do this, template oligonucleotides 
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were suspended to a concentration of 100 micromolar in nuclease free water. The templates were 
then hybridized to the T7 promoter primer provided with the Silencer™ SiRNA construction kit 
by mixing two microliters of each one of the six oligonucleotides with six microliters 
hybridization buffer as well as two microliters T7 promoter primer. The mixture was then heated 
to 70 ⁰C for 5 minutes and subsequently allowed to sit at room temperature for an additional 5 
minutes. After hybridization with the T7 primer, the gap left behind was filled in with Klenow 
DNA polymerase. This was done by adding the following directly to each hybridization mixture: 
two microliters 10x Klenow reaction buffer, two microliters dNTP mid, four microliters 
nuclease-free water, and two microliters of Exo-Klenow enzyme. This mixture was mixed by 
slow pipetting and transferred to a 37⁰C bead-bath for 30 minutes. 
 To assemble the transcription reaction, two microliters of each of the previous samples 
combined in an ependorf tube on ice with the following: four microliters nuclease-free water, 10 
microliters NTP mix, two microliters 10x T7 reaction buffer, and two microliters T7 enzyme 
mix. It should be noted that a considerable degree of precipitate had formed on top of the T7 
reaction buffer which required vertexing to resuspend. All components were mixed by gentle 
pipetting and the reaction was incubated in a 37⁰C bead-bath for two hours. After the initial 
incubation, each of the primer pairs were combined (leaving six total samples) and allowed to 
continue incubation at 37⁰C overnight (12 hours). 
 After the samples had been incubated overnight, each ~40 microliter sample had the 
following added: six microliters digestion buffer, 2.5 microliters DNase, three microliters RNase, 
and 48.5 microliters nuclease-free water. This reaction was mixed by gentle pipetting and 
allowed to incubate for two hours at 37⁰C. After preparing both the siRNA biding buffer and 
siRNA wash buffer as described by the manufacturer, 400 microliters of siRNA binding buffer 
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was added to each sample and allowed to incubate for 5 minutes at room temperature. Nuclease-
free water was then heated to 75⁰C for later use. Six siRNA filter cartridges were placed into 
2mL collection tubes and 100 microliters siRNA wash buffer was added to each of these 
cartridges. Each siRNA sample with binding buffer was added to separate tubes and centrifuged 
at 10,000 x g for one minute. The flow-through of each sample was discarded and the collection 
tubes were replaced. Each cartridge was then washed twice with 500 microliters siRNA wash 
buffer by spinning the columns at 10,000 x G for one minute with the flow-through being 
discarded. Finally, siRNA was eluted from each cartridge by adding 100 microliters nuclease-
free water heated to 75⁰C and centrifuging for 2 minutes at 12,000 x g. The siRNA created were 
stored at -80⁰C for later use. 
6.2.3 SiRNA Lipofection 
The eight separate siRNA samples created from previous steps were lipofected using 
Lipofectamine ™ RNAiMax lipofection reagent (Thermo Scientific). For each sample, fifty 
microliters Opti-MEM™ (Thermo Scientific) medium was combined with three microliters 
Lipofectamine™ RNAiMAX reagent. For each sample, in a separate tube, 50 microliters Opti-
MEM™ medium was combined with 10 picomoles siRNA (concentration determined by 
nanodrop). The diluted lipofectamine and diluted siRNA for each respective sample were then 
combined and allowed to incubate at room temperature for 5 minutes. 
6.2.4 Treatment of Cell Lines with SiRNA 
After allowing both the human Jurkat and human CD8+ anti-HPV cells to grow for 48 
hours, Cells were seeded at 200,000 cells per 190 microliters of media in a 96 well plate in 
triplicate. To each of these wells, ten microliters of the respective lipofected siRNA mix was 
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added (for an addition of one picomol siRNA per well). Samples were then allowed to incubate 
for 24 hours at 37⁰C and analyzed after incubation. 
6.2.5 qPCR 
One hundred microliters of each sample (approximately 100,000 cells) were removed 
from each well and processed through an RNeasy mini kit (Qiagen). Samples were spun down 
and their supernatant removed by gentle pipetting. The cell pellets that formed were resuspended 
in 350 microliters buffer RLT. These cells were then vortexed to homogenize, and added to 
RNeasy spin columns placed in collection tubes. These samples were then spun at 8,000 x g for 
15 seconds and their flow-through discarded. After this, 700 microliters buffer RW1 was added 
to each sample, centrifuged at 8,000 x g for 15 seconds, and the flow-through again discarded. 
Two separate 500 microliter aliquots of buffer RPE were then added to each sample, centrifuged 
at 8,000 x g for 15 seconds, and the flow through discarded. After having placed each sample in 
a fresh collection tube, the RNA was eluted by placing 30 microliters of RNase-free water to 
each column and centrifuging at 8,000 x g for a final minute. 
After each samples RNA had been isolated, qPCR was performed using a SuperScript™ 
IV One-Step RT-PCR system (Invitrogen). The three genes being tested for each sample were 
TCRb, CD3, CD137, and β-actin (normalization). These samples used primers TCRb-f, TCRb-r, 
CD3-f, CD3-r, CD137-f, CD137-r, β-actin-f, and β-actin-r respectively. The sequences for these 
primers can be found in appendix a. To execute qPCR, 25 microliters 2x Platinum™ RT-PCR 
Master Mix was combined with two microliters of the previously created RNA samples, 2.5 
microliters of each sample’s respective primers at 10 micromolar (5 microliters primer per 
sample), 0.5 microliters superscript IV enzyme mix, and 17.5 microliters nuclease-free water. 
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These samples were then mixed by gentle pipetting and run under the following thermo-cycler 
parameters: 
Step Temperature Time 
Reverse Transcription 55C 1 minutes 
Denaturation 98C 2 minutes 
Amplification 98C 10 seconds 
(40 cycles) 58C 10 seconds 
  72C 1 minute 
Final Extension 72C 5 minutes 
 
After thermocycling, samples had their CT values normalized by their respective β-actin 
expression and were compared by the ΔΔCT method. All qPCR was performed in triplicate for 
each of the three replicates for each sample (for a total of 9 replicates for each treatment group). 
6.2.6 Cell Viability by Trypan Blue Count 
To quantify cell viability by direct count, 10 microliters of each sample were removed 
from each well and placed into separate microfuge tubes. To each tube, an equal volume of 
trypan blue was added. These cells were then counted under a microscope and their values 
compared to one another. This assay was performed for each of the triplicate for all samples. 
6.2.7 Cell Viability by MTS 
To quantify cell viability, MTS reagent (Abcam) was obtained. The remaining 90 
microliters microliters (~90,000 cells) of each well was combined with 10 microliters MTS 
reagent and incubated for 4 hours at 37⁰C. After brief agitation, the plate was analyzed 
spectrophotometrically at an absorbance value of 490 nm. 
6.3 Results 
6.3.1 qPCR Results 
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Gene expression for all samples were quantified relative to the negative control. The 
results for each of the three genes for both human Jurkat and human CD8+ anti-HPV cells can be 
seen in the graphs below: 
 
Figure 6.1. qPCR results for TCRb on human Jurkat cells. 
 
 
Figure 6.2. qPCR of TCRb for human CD8+ anti-HPV cells 
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Figure 6.3. qPCR results for CD3 on human Jurkat cells. 
 
 
Figure 6.4. qPCR of CD3 for human CD8+ anti-HPV cells 
 
-0.2 0 0.2 0.4 0.6 0.8 1 1.2
Negative Control
Computationally derived siRNA 1
Computationally derived siRNA 2
Computationally derived siRNA 3
"Shotgun" siRNA cocktail
"Shotgun" siRNA cocktail (human CD8+
anti-HSV)
qPCR of CD3 for Human Jurkat Cells
0 0.2 0.4 0.6 0.8 1 1.2
Negative Control
Computationally derived siRNA 1
Computationally derived siRNA 2
Computationally derived siRNA 3
"Shotgun" siRNA cocktail
"Shotgun" siRNA cocktail (human
Jurkat)




Figure 6.5. qPCR results for CD137 on human Jurkat cells. 
 
 
Figure 6.6. qPCR of CD137 for human CD8+ anti-HPV cells 
 
6.3.2 Cell Viability by MTS 
Cell viability via MTS was calculated relative to the negative control. The results for the 
human Jurkat cells can be seen in the graph below: 
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Figure 6.7. Cell viability count results utilizing MTS on human Jurkat cells 
 
All samples demonstrated no significant difference from the control with a P value > 0.05 for all 
comparisons. 
The results for the human CD8+ anti-HPV cells can be seen in the below graph: 
 
Figure 6.8. Cell viability results utilizing MTS on human CD8+ anti-HPV cells 
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All samples demonstrated no significant difference from the control with a P value > 0.05 for all 
comparisons. 
6.3.3 Cell Viability by Trypan Blue 
Cell viability via Trypan blue was quantified relative to the negative control. The results 
for human Jurkat cells can be seen below: 
 
Figure 6.9. Cell viability count results utilizing trypan blue on human Jurkat cells 
 
All samples demonstrated no significant difference from the control with a P value > 0.05 for all 
comparisons. 
Results for the human CD8+ anti-HPV cells can be seen here: 
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Figure 6.10. Cell viability count results utilizing trypan blue on human CD8+ anti-HPV cells 
 
All samples with the exception of the computationally derived siRNA #1 did not vary 
significantly from the control with a P value > 0.05.  
6.4 Discussion 
 These results demonstrated a high level of effectiveness for all siRNA species targeting 
TCRb. Additionally, cocktails for human Jurkat used to treat human CD8+ anti-HPV cells had a 
minimal effect on gene expression. The reverse observation was the same, with siRNA 
synthesized for human CD8+ anti-HPV cells having minimal effect on human Jurkat cells. These 
observations taken together not only demonstrate the potency of siRNA synthesized with the 
methods outlined, but the high level of targeting specificity was demonstrated as well. It should 
be noted that only a single siRNA species seemed to have an impact on cell viability, meaning 
that the siRNAs elicit their effect on cells by inhibiting gene expression and not by a directly 
toxic mechanism. Though all siRNA were effective, siRNA synthesized with the previously 
described “shotgun” method demonstrated the highest level of effectiveness at gene suppression 
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for all genes tested. This is likely because of the large array of siRNA species created when 
making siRNA in this manner. 
 T cells that are incapable of expressing TCRb are physiologically unable to elicit an 
inflammatory response. If a T cell cannot elicit an inflammatory response, it is unable to 
proliferate. Given the high level of effectiveness for siRNAs which have been prudently 
synthesized to knock down the expression of TCRb, these siRNA species are potentially a 
potent, novel means of therapy for the treatment of autoimmunity. 
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Appendix A. Primer Sequences 


























































Human Jurkat 1-1 AAGAAUCGAUUGUUGGGCAUACCCCTGTCTC 
Human Jurkat 1-2 AAGGUAUGCCCAACAAUCGAUUCCCTGTCTC 
Human Jurkat 2-1 AAACCAGGACCCCAGAAGAGAAUCCTGTCTC 
Human Jurkat 2-2 AAAUUCUCUUCUGGGGUCCUGGUCCTGTCTC 
Human Jurkat 3-1 AAAGGGUUACAUGACCCGAAAUUCCTGTCTC 
Human Jurkat 3-2 AAAAUUUCGGGUCAUGUAACCCUCCTGTCTC 
Human CD8+ Anti-HPV 1-1 AAGCUUAGCUCUAAGGUGUCAGGCCTGTCTC 
Human CD8+ Anti-HPV 1-2 AACCUGACACCUUAGAGCUAAGCCCTGTCTC 
Human CD8+ Anti-HPV 2-1 AAGAUUAUCAUGUCCAGAAAUUGCCTGTCTC 
Human CD8+ Anti-HPV 2-2 AACAAUUUCUGGACAUGAUAAUCCCTGTCTC 
Human CD8+ Anti-HPV 3-1 AAGCCUGGAAACCAUGCUAAGCUCCTGTCTC 




Appendix B. TCRb siRNA Solver Source Code 
Figure 8.1. User Interface 
8.1 User Interface Source Code 
 
_ Partial Class Form1 Inherits System.Windows.Forms.Form 
 
'Form overrides dispose to clean up the component list. 
<System.Diagnostics.DebuggerNonUserCode()> _ 
Protected Overrides Sub Dispose(ByVal disposing As Boolean) 
    Try 
        If disposing AndAlso components IsNot Nothing Then 
            components.Dispose() 
        End If 
    Finally 
        MyBase.Dispose(disposing) 





'Required by the Windows Form Designer 
Private components As System.ComponentModel.IContainer 
 
'NOTE: The following procedure is required by the Windows Form Designer 
'It can be modified using the Windows Form Designer.   
'Do not modify it using the code editor. 
<System.Diagnostics.DebuggerStepThrough()> _ 
Private Sub InitializeComponent() 
    Me.Button1 = New System.Windows.Forms.Button() 
    Me.TextBox1 = New System.Windows.Forms.TextBox() 
    Me.TextBox2 = New System.Windows.Forms.TextBox() 
    Me.RichTextBox1 = New System.Windows.Forms.RichTextBox() 
    Me.CheckBox1 = New System.Windows.Forms.CheckBox() 
    Me.CheckBox2 = New System.Windows.Forms.CheckBox() 
    Me.RichTextBox2 = New System.Windows.Forms.RichTextBox() 
    Me.CheckBox3 = New System.Windows.Forms.CheckBox() 
    Me.TextBox3 = New System.Windows.Forms.TextBox() 
    Me.Label1 = New System.Windows.Forms.Label() 
    Me.Label2 = New System.Windows.Forms.Label() 
    Me.Label3 = New System.Windows.Forms.Label() 
    Me.TextBox4 = New System.Windows.Forms.TextBox() 
    Me.RichTextBox3 = New System.Windows.Forms.RichTextBox() 
    Me.RichTextBox4 = New System.Windows.Forms.RichTextBox() 
    Me.RichTextBox5 = New System.Windows.Forms.RichTextBox() 
    Me.Label4 = New System.Windows.Forms.Label() 
    Me.Label5 = New System.Windows.Forms.Label() 
    Me.Label6 = New System.Windows.Forms.Label() 
    Me.RichTextBox6 = New System.Windows.Forms.RichTextBox() 
    Me.Label8 = New System.Windows.Forms.Label() 
    Me.Label9 = New System.Windows.Forms.Label() 
    Me.Label10 = New System.Windows.Forms.Label() 
    Me.Label7 = New System.Windows.Forms.Label() 
    Me.Label11 = New System.Windows.Forms.Label() 
    Me.SuspendLayout() 
    ' 
    'Button1 
    ' 
    Me.Button1.Location = New System.Drawing.Point(237, 213) 
    Me.Button1.Name = "Button1" 
    Me.Button1.Size = New System.Drawing.Size(75, 23) 
    Me.Button1.TabIndex = 0 
    Me.Button1.Text = "Run" 
    Me.Button1.UseVisualStyleBackColor = True 
    ' 
    'TextBox1 
    ' 
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    Me.TextBox1.Location = New System.Drawing.Point(12, 35) 
    Me.TextBox1.Name = "TextBox1" 
    Me.TextBox1.Size = New System.Drawing.Size(300, 20) 
    Me.TextBox1.TabIndex = 2 
    ' 
    'TextBox2 
    ' 
    Me.TextBox2.Location = New System.Drawing.Point(12, 77) 
    Me.TextBox2.Name = "TextBox2" 
    Me.TextBox2.Size = New System.Drawing.Size(100, 20) 
    Me.TextBox2.TabIndex = 4 
    Me.TextBox2.Text = "23" 
    ' 
    'RichTextBox1 
    ' 
    Me.RichTextBox1.Location = New System.Drawing.Point(338, 34) 
    Me.RichTextBox1.Name = "RichTextBox1" 
    Me.RichTextBox1.Size = New System.Drawing.Size(234, 620) 
    Me.RichTextBox1.TabIndex = 5 
    Me.RichTextBox1.Text = "" 
    ' 
    'CheckBox1 
    ' 
    Me.CheckBox1.AutoSize = True 
    Me.CheckBox1.Location = New System.Drawing.Point(13, 104) 
    Me.CheckBox1.Name = "CheckBox1" 
    Me.CheckBox1.Size = New System.Drawing.Size(114, 17) 
    Me.CheckBox1.TabIndex = 6 
    Me.CheckBox1.Text = "Input is CDR3 only" 
    Me.CheckBox1.UseVisualStyleBackColor = True 
    ' 
    'CheckBox2 
    ' 
    Me.CheckBox2.AutoSize = True 
    Me.CheckBox2.Location = New System.Drawing.Point(13, 128) 
    Me.CheckBox2.Name = "CheckBox2" 
    Me.CheckBox2.Size = New System.Drawing.Size(86, 17) 
    Me.CheckBox2.TabIndex = 7 
    Me.CheckBox2.Text = "Input is DNA" 
    Me.CheckBox2.UseVisualStyleBackColor = True 
    ' 
    'RichTextBox2 
    ' 
    Me.RichTextBox2.Location = New System.Drawing.Point(12, 275) 
    Me.RichTextBox2.Name = "RichTextBox2" 
    Me.RichTextBox2.Size = New System.Drawing.Size(300, 80) 
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    Me.RichTextBox2.TabIndex = 8 
    Me.RichTextBox2.Text = "" 
    ' 
    'CheckBox3 
    ' 
    Me.CheckBox3.AutoSize = True 
    Me.CheckBox3.Location = New System.Drawing.Point(151, 104) 
    Me.CheckBox3.Name = "CheckBox3" 
    Me.CheckBox3.Size = New System.Drawing.Size(142, 17) 
    Me.CheckBox3.TabIndex = 9 
    Me.CheckBox3.Text = "Input is RNA compliment" 
    Me.CheckBox3.UseVisualStyleBackColor = True 
    ' 
    'TextBox3 
    ' 
    Me.TextBox3.Location = New System.Drawing.Point(49, 179) 
    Me.TextBox3.Name = "TextBox3" 
    Me.TextBox3.Size = New System.Drawing.Size(100, 20) 
    Me.TextBox3.TabIndex = 10 
    Me.TextBox3.Text = "0" 
    ' 
    'Label1 
    ' 
    Me.Label1.AutoSize = True 
    Me.Label1.Location = New System.Drawing.Point(13, 156) 
    Me.Label1.Name = "Label1" 
    Me.Label1.Size = New System.Drawing.Size(58, 13) 
    Me.Label1.TabIndex = 12 
    Me.Label1.Text = "Trim bases" 
    ' 
    'Label2 
    ' 
    Me.Label2.AutoSize = True 
    Me.Label2.Location = New System.Drawing.Point(13, 182) 
    Me.Label2.Name = "Label2" 
    Me.Label2.Size = New System.Drawing.Size(34, 13) 
    Me.Label2.TabIndex = 13 
    Me.Label2.Text = "Front:" 
    ' 
    'Label3 
    ' 
    Me.Label3.AutoSize = True 
    Me.Label3.Location = New System.Drawing.Point(13, 216) 
    Me.Label3.Name = "Label3" 
    Me.Label3.Size = New System.Drawing.Size(35, 13) 
    Me.Label3.TabIndex = 14 
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    Me.Label3.Text = "Back:" 
    ' 
    'TextBox4 
    ' 
    Me.TextBox4.Location = New System.Drawing.Point(50, 213) 
    Me.TextBox4.Name = "TextBox4" 
    Me.TextBox4.Size = New System.Drawing.Size(100, 20) 
    Me.TextBox4.TabIndex = 15 
    Me.TextBox4.Text = "0" 
    ' 
    'RichTextBox3 
    ' 
    Me.RichTextBox3.Location = New System.Drawing.Point(12, 376) 
    Me.RichTextBox3.Name = "RichTextBox3" 
    Me.RichTextBox3.Size = New System.Drawing.Size(300, 80) 
    Me.RichTextBox3.TabIndex = 16 
    Me.RichTextBox3.Text = "" 
    ' 
    'RichTextBox4 
    ' 
    Me.RichTextBox4.Location = New System.Drawing.Point(13, 475) 
    Me.RichTextBox4.Name = "RichTextBox4" 
    Me.RichTextBox4.Size = New System.Drawing.Size(300, 80) 
    Me.RichTextBox4.TabIndex = 17 
    Me.RichTextBox4.Text = "" 
    ' 
    'RichTextBox5 
    ' 
    Me.RichTextBox5.Location = New System.Drawing.Point(12, 576) 
    Me.RichTextBox5.Name = "RichTextBox5" 
    Me.RichTextBox5.Size = New System.Drawing.Size(300, 80) 
    Me.RichTextBox5.TabIndex = 18 
    Me.RichTextBox5.Text = "" 
    ' 
    'Label4 
    ' 
    Me.Label4.AutoSize = True 
    Me.Label4.Location = New System.Drawing.Point(13, 252) 
    Me.Label4.Name = "Label4" 
    Me.Label4.Size = New System.Drawing.Size(82, 13) 
    Me.Label4.TabIndex = 19 
    Me.Label4.Text = "Variable Region" 
    ' 
    'Label5 
    ' 
    Me.Label5.AutoSize = True 
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    Me.Label5.Location = New System.Drawing.Point(13, 360) 
    Me.Label5.Name = "Label5" 
    Me.Label5.Size = New System.Drawing.Size(84, 13) 
    Me.Label5.TabIndex = 20 
    Me.Label5.Text = "Diversity Region" 
    ' 
    'Label6 
    ' 
    Me.Label6.AutoSize = True 
    Me.Label6.Location = New System.Drawing.Point(13, 459) 
    Me.Label6.Name = "Label6" 
    Me.Label6.Size = New System.Drawing.Size(77, 13) 
    Me.Label6.TabIndex = 21 
    Me.Label6.Text = "Joining Region" 
    ' 
    'RichTextBox6 
    ' 
    Me.RichTextBox6.Location = New System.Drawing.Point(590, 34) 
    Me.RichTextBox6.Name = "RichTextBox6" 
    Me.RichTextBox6.Size = New System.Drawing.Size(324, 620) 
    Me.RichTextBox6.TabIndex = 22 
    Me.RichTextBox6.Text = "" 
    ' 
    'Label8 
    ' 
    Me.Label8.AutoSize = True 
    Me.Label8.Location = New System.Drawing.Point(341, 16) 
    Me.Label8.Name = "Label8" 
    Me.Label8.Size = New System.Drawing.Size(85, 13) 
    Me.Label8.TabIndex = 24 
    Me.Label8.Text = "siRNA Rankings" 
    ' 
    'Label9 
    ' 
    Me.Label9.AutoSize = True 
    Me.Label9.Location = New System.Drawing.Point(593, 15) 
    Me.Label9.Name = "Label9" 
    Me.Label9.Size = New System.Drawing.Size(104, 13) 
    Me.Label9.TabIndex = 25 
    Me.Label9.Text = "siRNA with Promoter" 
    ' 
    'Label10 
    ' 
    Me.Label10.AutoSize = True 
    Me.Label10.Location = New System.Drawing.Point(13, 560) 
    Me.Label10.Name = "Label10" 
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    Me.Label10.Size = New System.Drawing.Size(86, 13) 
    Me.Label10.TabIndex = 26 
    Me.Label10.Text = "Constant Region" 
    ' 
    'Label7 
    ' 
    Me.Label7.AutoSize = True 
    Me.Label7.Location = New System.Drawing.Point(13, 17) 
    Me.Label7.Name = "Label7" 
    Me.Label7.Size = New System.Drawing.Size(136, 13) 
    Me.Label7.TabIndex = 27 
    Me.Label7.Text = "Input TCRb sequence here" 
    ' 
    'Label11 
    ' 
    Me.Label11.AutoSize = True 
    Me.Label11.Location = New System.Drawing.Point(13, 59) 
    Me.Label11.Name = "Label11" 
    Me.Label11.Size = New System.Drawing.Size(73, 13) 
    Me.Label11.TabIndex = 28 
    Me.Label11.Text = "siRNA Length" 
    ' 
    'Form1 
    ' 
    Me.AutoScaleDimensions = New System.Drawing.SizeF(6.0!, 13.0!) 
    Me.AutoScaleMode = System.Windows.Forms.AutoScaleMode.Font 
    Me.ClientSize = New System.Drawing.Size(926, 666) 
    Me.Controls.Add(Me.Label11) 
    Me.Controls.Add(Me.Label7) 
    Me.Controls.Add(Me.Label10) 
    Me.Controls.Add(Me.Label9) 
    Me.Controls.Add(Me.Label8) 
    Me.Controls.Add(Me.RichTextBox6) 
    Me.Controls.Add(Me.Label6) 
    Me.Controls.Add(Me.Label5) 
    Me.Controls.Add(Me.Label4) 
    Me.Controls.Add(Me.RichTextBox5) 
    Me.Controls.Add(Me.RichTextBox4) 
    Me.Controls.Add(Me.RichTextBox3) 
    Me.Controls.Add(Me.TextBox4) 
    Me.Controls.Add(Me.Label3) 
    Me.Controls.Add(Me.Label2) 
    Me.Controls.Add(Me.Label1) 
    Me.Controls.Add(Me.TextBox3) 
    Me.Controls.Add(Me.CheckBox3) 
    Me.Controls.Add(Me.RichTextBox2) 
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    Me.Controls.Add(Me.CheckBox2) 
    Me.Controls.Add(Me.CheckBox1) 
    Me.Controls.Add(Me.RichTextBox1) 
    Me.Controls.Add(Me.TextBox2) 
    Me.Controls.Add(Me.TextBox1) 
    Me.Controls.Add(Me.Button1) 
    Me.Name = "Form1" 
    Me.Text = "TCRb siRNA Solver" 
    Me.ResumeLayout(False) 




Friend WithEvents Button1 As Button 
Friend WithEvents TextBox1 As TextBox 
Friend WithEvents TextBox2 As TextBox 
Friend WithEvents RichTextBox1 As RichTextBox 
Friend WithEvents CheckBox1 As CheckBox 
Friend WithEvents CheckBox2 As CheckBox 
Friend WithEvents RichTextBox2 As RichTextBox 
Friend WithEvents CheckBox3 As CheckBox 
Friend WithEvents TextBox3 As TextBox 
Friend WithEvents Label1 As Label 
Friend WithEvents Label2 As Label 
Friend WithEvents Label3 As Label 
Friend WithEvents TextBox4 As TextBox 
Friend WithEvents RichTextBox3 As RichTextBox 
Friend WithEvents RichTextBox4 As RichTextBox 
Friend WithEvents RichTextBox5 As RichTextBox 
Friend WithEvents Label4 As Label 
Friend WithEvents Label5 As Label 
Friend WithEvents Label6 As Label 
Friend WithEvents RichTextBox6 As RichTextBox 
Friend WithEvents Label8 As Label 
Friend WithEvents Label9 As Label 
Friend WithEvents Label10 As Label 
Friend WithEvents Label7 As Label 
Friend WithEvents Label11 As Label 
End Class 
 
8.2 Non-interface source code 
 
Public Class Form 1 





    MsgBox("An error has occured. Please check your inputs and try again.") 
 




'Scans respective siRNA regions for whether or not they meet The first Descrim as defined by 
Reynalds et al 
'SiRNA has a base of A in position 3 
'Returns a boolean value 
Function Discrim1(ByVal siRNA As String) As Boolean 
 
    Dim bool As Boolean = False 
 
    'Checks specified position for specified character 
    If GetChar(siRNA, 3) = "a" Or GetChar(siRNA, 3) = "A" Then 
        bool = True 
    End If 
 




'Scans respective siRNA regions for whether or not they meet The second Descrim as defined by 
Reynalds et al 
'SiRNA has a base of A in position 19 
'Returns a boolean value 
Function Discrim2(ByVal siRNA As String) As Boolean 
 
    Dim bool As Boolean = False 
 
    'Checks specified position for specified character 
    If GetChar(siRNA, 19) = "a" Or GetChar(siRNA, 19) = "A" Then 
        bool = True 
    End If 
 




'Scans respective siRNA regions for whether or not they meet the third Descrim as defined by 
Reynalds et al 
'SiRNA does not have a base of G in position 13 
'Returns a boolean value 




    Dim bool As Boolean = False 
 
    'Checks specified position for specified character 
    If Not GetChar(siRNA, 13) = "g" And Not GetChar(siRNA, 13) = "G" Then 
        bool = True 
    End If 
 




'Scans respective siRNA regions for whether or not they meet the fourth Descrim as defined by 
Reynalds et al 
'SiRNA has a base of U in position 10 
'Returns a boolean value 
Function Discrim4(ByVal siRNA As String) As Boolean 
 
    Dim bool As Boolean = False 
 
    'Checks specified position for specified character 
    If GetChar(siRNA, 10) = "u" Or GetChar(siRNA, 10) = "U" Then 
        bool = True 
    End If 
 





'Scans respective siRNA regions for whether or not they meet the fifth Descrim as defined by 
Reynalds et al 
'SiRNA does not have a base of C or G in position 19 
'Returns a boolean value 
Function Discrim5(ByVal siRNA As String) As Boolean 
 
    Dim bool As Boolean = False 
 
    'Checks specified position for specified character 
    If Not GetChar(siRNA, 19) = "c" And Not GetChar(siRNA, 19) = "C" And Not 
GetChar(siRNA, 19) = "g" And Not GetChar(siRNA, 19) = "G" Then 
        bool = True 
    End If 
 






'Checks a substring of each siRNA for a palindromic sequence encompassing of 4 bases 
'Returns a boolean value 
Function Palindrome_check_4_units(ByVal siRNA As String) As Boolean 
 
    Dim bool As Boolean = False 
 
    Dim reverse_sequence As String = Strings.StrReverse(siRNA) 
    Dim count As Integer = 0 
 
    Dim forward As String = Nothing 
    Dim reverse As String = Nothing 
 
    'Splits sequence into substrings and compares them against their compliment 
    Do While count < siRNA.Length - 4 
        forward = siRNA.Remove(0, count) 
        forward = siRNA.Substring(0, 4) 
        Dim count2 As Integer = 0 
        Do While count2 < siRNA.Length - 4 
            reverse = siRNA.Remove(0, count) 
            reverse = siRNA.Substring(0, 4) 
            If forward = reverse Then 
                bool = True 
            End If 
            count2 = count2 + 1 
        Loop 
 
        count = count + 1 
 
    Loop 
 




'Checks a substring of each siRNA for a palindromic sequence encompassing of 5 bases 
'Returns a boolean value 
Function Palindrome_check_5_units(ByVal siRNA As String) As Boolean 
 
    Dim bool As Boolean = False 
 
    Dim reverse_sequence As String = Strings.StrReverse(siRNA) 
    Dim count As Integer = 0 
 
    Dim forward As String = Nothing 




    'Splits sequence into substrings and compares them against their compliment 
    Do While count < siRNA.Length - 5 
        forward = siRNA.Remove(0, count) 
        forward = siRNA.Substring(0, 5) 
        Dim count2 As Integer = 0 
        Do While count2 < siRNA.Length - 5 
            reverse = siRNA.Remove(0, count) 
            reverse = siRNA.Substring(0, 5) 
            If forward = reverse Then 
                bool = True 
            End If 
            count2 = count2 + 1 
        Loop 
 
        count = count + 1 
 
    Loop 
 




'Checks for the GC content of an siRNA input 
'Returns a value between 0 and 1 
Function Get_GC(ByVal siRNA As String, siRNA_length As Integer) As Double 
 
    Dim GC_content As Double = 0 
 
    Dim count As Integer = 0 
    Dim ATU_count As Integer = 0 
 
    Do While count < siRNA.Length 
 
        If GetChar(siRNA, count + 1) = "a" Or GetChar(siRNA, count + 1) = "A" Or 
GetChar(siRNA, count + 1) = "t" Or GetChar(siRNA, count + 1) = "T" Or GetChar(siRNA, 
count + 1) = "u" Or GetChar(siRNA, count + 1) = "U" Then 
 
            ATU_count = ATU_count + 1 
 
        End If 
 
        count = count + 1 
 




    GC_content = 1 - (ATU_count / siRNA_length) 
 




'Checks whether or not an A or U is present in positions 15-19 as specified in Reynalds et al 
'Returns boolean value 
Function AUT_in_15_through_19(ByVal sirna As String, sirna_ength As Integer) As Boolean 
 
    Dim bool As Boolean = False 
 
    'Load characters from siRNA into variables 
    Dim char15 As Char = GetChar(sirna, 15) 
    Dim char16 As Char = GetChar(sirna, 16) 
    Dim char17 As Char = GetChar(sirna, 17) 
    Dim char18 As Char = GetChar(sirna, 18) 
    Dim char19 As Char = GetChar(sirna, 19) 
 
    'Check above variables for presence of A, U, or T 
    If char15 = "a" Or char15 = "A" Or char15 = "t" Or char15 = "T" Or char15 = "u" Or char15 = 
"U" Then 
        bool = True 
    End If 
 
    If char16 = "a" Or char16 = "A" Or char16 = "t" Or char16 = "T" Or char16 = "u" Or char16 = 
"U" Then 
        bool = True 
    End If 
 
    If char17 = "a" Or char17 = "A" Or char17 = "t" Or char17 = "T" Or char17 = "u" Or char17 = 
"U" Then 
        bool = True 
    End If 
 
    If char18 = "a" Or char18 = "A" Or char18 = "t" Or char18 = "T" Or char18 = "u" Or char18 = 
"U" Then 
        bool = True 
    End If 
 
    If char19 = "a" Or char19 = "A" Or char19 = "t" Or char19 = "T" Or char19 = "u" Or char19 = 
"U" Then 
        bool = True 
    End If 
 






'Checks for a leading sequence of AA at the start of respective siRNA 
'returns boolean value 
Function Check_for_AA(ByVal siRNA As String) As Boolean 
 
    Dim AA_Bool As Boolean = False 
 
    Dim Score As Integer = 0 
 
    'For each A in the first two residues, the variable "score" is iterated by 1 
    If GetChar(siRNA, 1) = "A" Or GetChar(siRNA, 1) = "a" Then 
        Score = Score + 1 
    End If 
 
    If GetChar(siRNA, 2) = "A" Or GetChar(siRNA, 2) = "a" Then 
        Score = Score + 1 
    End If 
 
    'Score being equal to 2 indicated that both of the leading residues Is A 
    If Score = 2 Then 
        AA_Bool = True 
    End If 
 




'Checks for running sequences of A or T (variouse literature indicates that this can cause 
dissociation of siRNA from RISC) 
'returns boolean value 
Function Check_for_running_T_or_A(ByVal siRNA As String, sirna_length As Integer) As 
Boolean 
 
    Dim Poly_T_A As Boolean = False 
 
    Dim count As Integer = 0 
    Dim tempstring As String = Nothing 
 
    Do While count < sirna_length - 4 
        tempstring = siRNA 
        tempstring = tempstring.Remove(0, count) 'remove leading characters in temporary string 
        tempstring = tempstring.Substring(0, 4) ' trims temporary string to 4 characters 
 
        'Checks for a polly A or poly T sequence 
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        If tempstring = "aaaa" Or tempstring = "AAAA" Or tempstring = "TTTT" Or tempstring = 
"tttt" Or tempstring = "UUUU" Or tempstring = "uuuu" Then 
            Poly_T_A = True 
            count = 9999999 'breaks loop 
        End If 
 
        count = count + 1 
 
    Loop 
 




'Converts an input of a DNA sequence into its reverse complimentary RNA counterpart 
'Returns string a value 
Function Convert_to_RNA(Input As String) 
 
    Dim Sequence(Input.Length) As String 
    Dim Working_String(Input.Length) As String 
    Dim count As Integer = 0 
 
    'Loads input into an array for conversion 
    Do While count < Input.Length 
        Sequence(count) = Input(count) 
 
        count = count + 1 
 
    Loop 
 
    'Reverses the DNA input (this is important because we are interested in the reverse 
compliment sequence) 
    Array.Reverse(Sequence) 
    count = 1 
    Dim Return_string As String = Nothing 
 
    'Converts first array sequence into complimentary values for second array 
    Do While count < Working_String.Length - 1 
 
        Select Case Sequence(count) 
            Case "A" 
                Working_String(count) = "U" 
 
            Case "a" 




            Case "T" 
                Working_String(count) = "A" 
 
            Case "t" 
                Working_String(count) = "A" 
 
            Case "C" 
                Working_String(count) = "G" 
 
            Case "c" 
                Working_String(count) = "G" 
 
            Case "G" 
                Working_String(count) = "C" 
 
            Case "g" 
                Working_String(count) = "C" 
 
            Case Else 
                Throw_error() 
 
        End Select 
 
        count = count + 1 
 
    Loop 
 
    count = 0 
 
    'Converts array of characters into a normal string for the function to return 
    Do While count < Working_String.Length 
 
        Return_string = Return_string + Working_String(count) 
 
        count = count + 1 
 
    Loop 
 





'Converts an input of a RNA sequence into its reverse complimentary RNA counterpart 
'Returns string a value 




    Dim Sequence(Input.Length) As String 
    Dim Working_String(Input.Length) As String 
    Dim count As Integer = 0 
 
    'Loads input into an array for conversion 
    Do While count < Input.Length 
        Sequence(count) = Input(count) 
 
        count = count + 1 
 
    Loop 
 
    'Reverses the DNA input (this is important because we are interested in the reverse 
compliment sequence) 
    Array.Reverse(Sequence) 
    count = 1 
    Dim Return_string As String = Nothing 
 
    'Converts first array sequence into complimentary values for second array 
    Do While count < Working_String.Length - 2 
 
        Select Case Sequence(count) 
            Case "A" 
                Working_String(count) = "U" 
 
            Case "a" 
                Working_String(count) = "U" 
 
            Case "U" 
                Working_String(count) = "A" 
 
            Case "u" 
                Working_String(count) = "A" 
 
            Case "t" 
                Working_String(count) = "A" 
 
            Case "T" 
                Working_String(count) = "A" 
 
            Case "C" 
                Working_String(count) = "G" 
 
            Case "c" 




            Case "G" 
                Working_String(count) = "C" 
 
            Case "g" 
                Working_String(count) = "C" 
 
            Case Else 
                Throw_error() 
 
        End Select 
 
        count = count + 1 
 
    Loop 
 
    count = 0 
 
    'Converts array of characters into a normal string for the function to return 
    Do While count < Working_String.Length 
 
        Return_string = Return_string + Working_String(count) 
 
        count = count + 1 
 
    Loop 
 




'Checks that values within text boxes are of the data type needed 
'Calls Throw_error() sub-procedure if any of the tests are positive 
Sub Error_Checks() 
 
    TextBox1.Text.ToUpper() 
 
    Dim Check_TB2 As Integer 
 
    If Not Integer.TryParse(TextBox2.Text, Check_TB2) Then 
        Throw_error() 
    End If 
 
    Dim Check_TB3 As Integer 
 
    If Not Integer.TryParse(TextBox3.Text, Check_TB3) Then 
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        Throw_error() 
    End If 
 
    Dim Check_TB4 As Integer 
 
    If Not Integer.TryParse(TextBox4.Text, Check_TB4) Then 
        Throw_error() 




'Sequence of events called when User hits the "Run" button 
Private Sub Button1_Click(sender As Object, e As EventArgs) Handles Button1.Click 
 
    'Resets output 
    RichTextBox1.Text = Nothing 
Region "Trim nucleic acid sequence" 
    'Trims front of siRNA sequence if specified by user to do so 
    If Not TextBox2.Text = Nothing Then 
        Dim FrontTrim As Integer = CInt(TextBox3.Text) 
        TextBox1.Text = TextBox1.Text.Remove(0, FrontTrim) 
    End If 
 
    'Trims back of siRNA sequence if specified by user to do so 
    If Not TextBox3.Text = Nothing Then 
        Dim BackTrim As Integer = CInt(TextBox4.Text) 
        Dim TempVar As Integer = TextBox1.Text.Length 
        TextBox1.Text = TextBox1.Text.Substring(0, TempVar - BackTrim) 
    End If 
 
End Region 
    'Calls subprocedure to convert input from a DNA sequence to a reverse complimentary RNA 
sequence if specified by user 
    If CheckBox2.Checked Then 
        TextBox1.Text = Convert_to_RNA(TextBox1.Text) 
    End If 
 
    'Calls subprocedure to convert input from a RNA sequence to a reverse complimentary RNA 
sequence if specified by user 
    If CheckBox3.Checked Then 
        TextBox1.Text = Convert_to_Compliment(TextBox1.Text) 
    End If 
 




    'Initializes arrays which tore siRNA candidates and their corresponding scores 
    Dim DataArray(50000) As String 
    Dim ScoreArray(50000) As Double 
 
    Dim codelength As Integer = 0 
    codelength = TextBox1.Text.Length 
    Dim SiRNA_Length = Convert.ToInt32(TextBox2.Text) 
    Dim count As Integer = 0 
 
 
    'Loads siRNA candidates into an array of length specified by user 
Region "Load siRNA Array" 
    Do While count < codelength - SiRNA_Length 'load siRNAs into array 
 
        DataArray(count) = TextBox1.Text 
        DataArray(count) = DataArray(count).Remove(0, count) 'remove leading characters in 
string 
        DataArray(count) = DataArray(count).Substring(0, SiRNA_Length) 'remove following 
characters after siRNA 
 
        count = count + 1 
 
    Loop 
End Region 
    count = 0 
 
    'Seperates V, D, J, and C regions 
Region "separate regions" 
    If Not CheckBox1.Checked Then 
 
        Do While TextBox1.Text.Length > count 
 
            If count <= 340 Then 
 
                RichTextBox2.Text = RichTextBox2.Text + GetChar(TextBox1.Text, count + 1) 
 
            End If 
 
            If count > 340 And count <= 356 Then 
 
                RichTextBox3.Text = RichTextBox3.Text + GetChar(TextBox1.Text, count + 1) 
 




            If count > 356 And count <= 406 Then 
 
                RichTextBox4.Text = RichTextBox4.Text + GetChar(TextBox1.Text, count + 1) 
 
            End If 
 
            If count > 406 Then 
 
                RichTextBox5.Text = RichTextBox5.Text + GetChar(TextBox1.Text, count + 1) 
 
            End If 
 
            count = count + 1 
 
        Loop 
 
    End If 
End Region 
    count = 0 
 
    'Adds scores 
    'Values added to each siRNA score are largely determined by their level of significance-  
    '-RNAi as determined by Reynalds et al 
Region "Tally Scores" 
    Do While count < codelength - SiRNA_Length 
 
        'calls function to determine GC content of siRNA 
        Dim GC_content As Double = Get_GC(DataArray(count), SiRNA_Length) 
 
        If Discrim1(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 16.8 
        End If 
 
        If Discrim2(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 22.1 
        End If 
 
        If Discrim3(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 14.1 
        End If 
 
        If Discrim4(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 30.6 




        If Discrim5(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 25.6 
        End If 
 
        If not Palindrome_check_4_units(DataArray(count)) And not 
Palindrome_check_5_units(DataArray(count)) Then 
            SiRNA_Score = SiRNA_Score + 10.1 
        End If 
 
        If AUT_in_15_through_19(DataArray(count), DataArray(count).Length) Then 
            SiRNA_Score = SiRNA_Score + 16.9 
        End If 
 
        'SiRNA with running A or T regions are not candidates for successful inhibition 
        If Check_for_running_T_or_A(DataArray(count), DataArray(count).Length) Then 
            'Lowers score to a level where they will be ignored by future algorithms 
            SiRNA_Score = SiRNA_Score - 20000 
        End If 
 
        'SiRNA with running A or T regions are not candidates for successful inhibition 
        If Not Check_for_AA(DataArray(count)) Then 
            'Lowers score to a level where they will be ignored by future algorithms 
            SiRNA_Score = SiRNA_Score - 20000 
        End If 
 
        'SiRNA with running A or T regions are not candidates for successful inhibition 
        If Get_GC(DataArray(count), DataArray(count).Length) < 0.3 Or 
Get_GC(DataArray(count), DataArray(count).Length) > 0.52 Then 
            'Lowers score to a level where they will be ignored by future algorithms 
            SiRNA_Score = SiRNA_Score - 20000 
        End If 
 
        ScoreArray(count) = SiRNA_Score 
 
        SiRNA_Score = 0 
 
        count = count + 1 
 
    Loop 
End Region 
    'Sorts array in accending order based on the assigned score 
    Array.Sort(ScoreArray, DataArray) 
 
    'Reverses array so it will be sequenced in decending order for the user 
    Array.Reverse(ScoreArray) 




    count = 0 
 
    'Displays resulting siRNA candidates and their respective scores to the user 
    Do While count < codelength - SiRNA_Length 
 
        If ScoreArray(count) > 0 Then 
 
            'Displays siRNA candidate with respective score adjacent 
            RichTextBox1.Text = RichTextBox1.Text + DataArray(count) + "   " + 
ScoreArray(count).ToString + vbCrLf 
 
            'Displays siRNA candidate with the promoter sequence added 
            RichTextBox6.Text = RichTextBox6.Text + DataArray(count) + "CCTGTCTC" + "        
" + ScoreArray(count).ToString + vbCrLf 
 
            'Removes leading AA to get compliment without overhang 
            DataArray(count).Remove(0, 2) 
 
            'Displays compliment and adds promoter sequence as well as AA overhang to the 
compliment 
            RichTextBox6.Text = RichTextBox6.Text + "AA" + 
Convert_to_Compliment(DataArray(count)) + "CCTGTCTC" + vbCrLf + vbCrLf 
 
        End If 
 
        count = count + 1 
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